

NIH Public Access

Author Manuscript

J Endocrinol. Author manuscript; available in PMC 2010 January 9

Published in final edited form as: *J Endocrinol.* 2007 March ; 192(3): 563–583. doi:10.1677/JOE-06-0158.

Unraveling the molecular targets pertinent to junction restructuring events during spermatogenesis using the Adjudininduced germ cell depletion model

Weiliang Xia, Dolores D Mruk, Will M Lee¹, and C Yan Cheng

Center for Biomedical Research, Population Council, 1230 York Avenue, New York, New York 10021, USA

¹ Department of Zoology, University of Hong Kong, Hong Kong, China

Abstract

During spermatogenesis, extensive restructuring takes place at the Sertoli-Sertoli and Sertoli-germ cell interface, which is regulated via intriguing interactions among cytokines, proteases, protease inhibitors, kinases, phosphatases, and transcription factors. This in turn determines the steady-state levels of integral membrane proteins at the cell junctions. We sought to further expand these observations using the Adjudin model. Adjudin is a potential male contraceptive that targets Sertoligerm cell adhesion, causing exfoliation of spermatids and spermatocytes, but not spermatogonia, from the seminiferous epithelium. This model thus provides the means to identify crucial regulatory molecules and signaling pathways pertinent to junction restructuring events during spermatogenesis. In this study, genome-wide expression profiling of rat testes after treatment with Adjudin at the time of extensive junction restructuring was performed. Differentially regulated genes, such as cytokines, proteases, protease inhibitors, cell junction-associated proteins, and transcription factors pertinent to junction restructuring were identified. These data were consistent with earlier findings; however, much new information was obtained which has been deposited at the Gene Expression Omnibus data repository website: http://www.ncbi.nih.gov/geo/ with Accession number: GSE5131. The primary signaling events pertinent to junction restructuring in the testis induced by Adjudin were also delineated using bioinformatics. These findings were also consistent with recently published reports. The identified molecular signatures or targets pertinent to junction dynamics in the testis as reported herein, many of which have not been investigated, thus offer a framework upon which the regulation of junction restructuring events at the Sertoli-Sertoli and Sertoli-germ cell interface pertinent to spermatogenesis can be further studied.

Introduction

In adult rat testes, spermatogonia (diploid, 2n) divide and differentiate into spermatids (haploid, 1n) while traversing the seminiferous epithelium from the basal to the apical compartment, reaching the luminal edge of the seminiferous epithelium to permit spermiation that occurs at stage VIII of the epithelial cycle. For spermatogonia to become fully developed elongate spermatids (i.e. spermatozoa) takes ~58 days in rats and spans ~4.5 rounds of the seminiferous epithelial cycle (~12–14 days per cycle in rats) with each cycle comprising 14 distinct stages that display unique association between Sertoli and germ cells at different developmental stages (Parvinen 1982, de Kretser & Kerr 1994). Thus, extensive restructuring at the Sertoli–Sertoli and Sertoli–germ cell interface is taking place in the seminiferous epithelium during

Requests for offprints should be addressed to C Y Cheng; y-cheng@popcbr.rockefeller.edu.

spermatogenesis (Cheng & Mruk 2002, Mruk & Cheng 2004b). Since different germ cells are arranged into layers across the epithelium and progressively migrate toward the seminiferous tubule lumen, their interactions with Sertoli cells also differ spatially (Russell 1977). It is well established that spermatogenesis is regulated by follicle-stimulating hormone (FSH) and testosterone under the influence of the hypothalamic-pituitary-testicular axis (de Kretser & Kerr 1994, Eddy 1998). However, crosstalk between Sertoli and germ cells in the seminiferous epithelium and their regulation pertinent to spermatogenesis and spermiogenesis remain largely unexplored. Recent studies have shown that the intriguing events of Sertoli–germ cell interactions at the cell-cell interface are regulated by cytokines (e.g. transforming growth factor (TGF)- β 3 and tumour necrosis factor $(TNF)\alpha$) that work in concert with proteases, protease inhibitors, kinases, and phosphatases in the microenvironment of the seminiferous epithelium behind the basement membrane. The collective interactions of these molecules determine the timely 'opening' and 'closing' of the blood-testis barrier (BTB) to facilitate preleptotene spermatocyte migration across the barrier and germ cell movement during the epithelial cycle (Mruk & Cheng 2004b). Additionally, supporting evidence for this local regulatory mechanism is derived from germ cell transplantation studies showing that rat spermatogonia injected into seminiferous tubules in mice differentiate independent of the surrounding milieu (for reviews, see McLean et al. 2001 and Matzuk 2004).

Adjudin [1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohy-drazide], formerly known as AF-2364, is a molecule that mediates adherens junction disruption at the Sertoli-germ cell interface (Mruk & Cheng 2004b). It is a derivative of lonidamine having a more potent aspermatogenic activity but less toxicity versus lonidamine (Cheng et al. 2001, Grima et al. 2001). When administered to adult rats by gavage, Adjudin exerts its effects primarily at the Sertoli-germ cell interface, causing germ cell sloughing, in particular elongating/elongate/ round spermatids and spermatocytes from the epithelium without perturbing adhesion between spermatogonia and Sertoli cells; as such, its effects are reversible (Mruk & Cheng 2004b, Cheng et al. 2005). Based on these initial observations, Adjudin has been used to develop an in vivo model to characterize cell-cell interactions and junction dynamics pertinent to spermatogenesis (Siu et al. 2003b, 2005, Lee & Cheng 2005, Xia & Cheng 2005, Yan & Cheng 2005, Xia et al. 2006). For instance, the integrin/focal adhesion kinase (FAK)/ phosphatidylinositol 3-kinase (PI-3) kinase/extracellular signal regulated kinase (ERK) signaling pathway was shown to regulate Sertoli–germ cell adherens junction (AJ) dynamics, particularly the apical ectoplasmic specialization (ES), using Adjudin-treated rat testes (Siu et al. 2003b, 2005). Furthermore, a loss of protein–protein interactions between integral membrane proteins and their adaptors at the AJ (e.g. apical and basal ES) to facilitate AJ and BTB restructuring were also detected using this model (Lee et al. 2005, Xia & Cheng 2005). This signal pathway activation and the loss of protein-adaptor interactions at the AJ were also demonstrated during spermatid loss from the epithelium, which was induced by suppressing intratesticular androgen level using testosterone and estrogen implants in adult rats (Wong et al. 2005, Xia et al. 2005b, Zhang et al. 2005). Collectively, these data clearly illustrate that the Adjudin model is a valuable tool to identify signaling pathways pertinent to AJ dynamics and possibly the regulatory mechanisms pertinent to spermatogenesis. Since DNA microarray technique has been widely used to unravel global transcriptional changes (for a review, see Stoughton 2005), we sought to identify these potential regulators of junction remodeling pertinent to spermatogenesis using expression microarray. In this report, we describe findings based on the use of Affymetrix Genechips (rat genome) that contain ~30 000 probe sets to characterize the expression profile in rat testes following treatment with Adjudin at the time of AJ restructuring. The genes and the signaling conduits identified by microarray could provide a framework to further probe the biological processes of junction restructuring pertinent to spermatogenesis.

Materials and Methods

Animals and microarray gene chips

Male Sprague–Dawley rats (~300 g b.w.) were purchased from Charles River Laboratories (Kingston, MA, USA). The use of animals in this study was approved by The Rockefeller University Animal Care and Use Committee, with protocol numbers 03017 and 06018. Rats were treated with a single dose of Adjudin at time 0 by gavage at 50 mg/kg body weight (b.w.) as described earlier (Cheng et al. 2001, Grima et al. 2001). For microarray analysis, rats (n=3 for time 0 and 96 h; n=2 for 8 h) were killed by CO₂ asphyxiation. These two time points were selected since by 8 h, even though some elongate and elongating spermatids had begun to exfoliate from the seminiferous epithelium, most germ cells remained attached to Sertoli cells in the seminiferous epithelium. Even for those that were detached from the epithelium, they were still found in the tubule lumen. As such, this is the time that extensive AJ restructuring was occurring at the Sertoli-germ cell interface, but germ cells remained in the samples being analyzed by microarray. By day 4, virtually all elongating/ elongate spermatids were depleted from the epithelium and most round spermatids and spermatocytes had left the epithelium and tubule lumen as well, suggesting the induced AJ restructuring had subsided as shown in earlier studies (Chen et al. 2003, Mruk & Cheng 2004a,b). Testes were frozen immediately in liquid nitrogen upon termination and stored at -80 °C until use for RNA extraction. Rat Genome 230 2.0 GeneChips were purchased from Affymetrix, Inc. (Santa Clara, CA, USA) and used for this study.

Total RNA preparation

About 0.1 g testis from each sample was used for total RNA isolation using TRIZOL (Invitrogen). RNA was then purified with an RNeasy cleanup kit (Qiagen). Total RNA quality was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).

cRNA labeling, hybridization, and array scanning

cDNA synthesis and cRNA labeling by in vitro transcription (IVT) were performed using GeneChip One-Cycle Target Labeling and Control Reagents (Affymetrix, P/N 900493). Briefly, total RNA (~5 µg) prepared as mentioned above was first reverse transcribed using a T7-oligo (dT) promoter primer in the first-strand cDNA synthesis reaction. Following RNase H-mediated second-strand cDNA synthesis, the double-stranded cDNA was purified and served as a template in the subsequent in vitro transcription reaction. The IVT reaction was carried out in the presence of T7 RNA polymerase and a biotinylated nucleotide analog/ ribonucleotide mix for cRNA amplification and biotinylation following the protocols provided by the manufacturer. The biotinylated cRNA targets were then purified using RNeasy spin columns, and fragmented at 94 °C for 35 min in a fragmentation buffer (40 mM Tris-acetate (pH 8.1) containing 100 mM potassium acetate and 30 mM magnesium acetate), which were used for hybridization with GeneChips. The integrity of the labeled cRNA was again assessed by Agilent 2100 Bioanalyzer before hybridization. The GeneChip Fluidics Station 450 was used for array hybridization and processing and the Affymetrix GeneChip Scanner 3000 for array scanning. cRNA labeling, hybridization, and array scanning were performed at The Rockefeller University Genomics Resource Center (New york, NY, USA). The experiment was repeated twice using different samples.

Microarray data analysis

Scanned images of the microarray were first visually examined to rule out physical anomalies or excessive high background. Data were initially accessed using the Microarray Suite 5.0 (MAS) software (Affymetrix) and all probe sets on each array were scaled to a target signal intensity of 250. This prescaling assured data uniformity in subsequent cross-chip comparison.

MAS assessment also reported the background noise, the number of probe sets that are present, marginal, or absent in the samples out of a total of 31 099 probe sets on Rat Genome 230 2.0 GeneChip based on signals. Data were then exported and analyzed using the GeneSpring software (Version 7.2, Agilent). All samples were grouped accordingly into time 0 (control), 8-h and 4-day post-Adjudin treatment. Data were normalized in three steps: step 1, data transformation to set measurements from <0.01 to 0.01. Step 2, per chip normalization to the median or 50th percentile intensity of the probe set in each chip to remove non-biological variations such as differences in the experiment conditions. Step 3, per gene normalization to normalize all samples to time 0 (the median value for each probe set among the three control samples was used). Data were further filtered using the filtering on flags feature (namely signal detection, present, marginal or absent; at least present or marginal in one of the sample after Adjudin treatment) in Genespring to identify genes that are expressed in one of the experimental conditions under study (e.g. Adjudin treatment) and expression raw value (at least 50) to remove unreliable genes. Thereafter, genes that were expressed differentially and were statistically significantly different from control (normal rat testes, P < 0.05) were determined by one-way ANOVA for multiple comparisons between samples in control (n = 3) and treatment groups (n=2 for 8 h or n=3 for 4-day post-Adjudin treatment) with multiple test correction (default option) and multiple test correction set to 'none', using the Agilent GeneSpring software. Genes with significant changes in their steady-state mRNA levels in comparison with control were scored and grouped. Hierarchical clustering analysis (unsupervised) was performed in the GeneSpring software using default settings. Gene ontology and signaling pathway analysis was performed using Onto Express and Pathway Express programs available from Wayne State University (Draghici et al. 2003a,b, Khatri et al. 2004, 2005). The Affymetrix probe set ID corresponding to the specific gene at the GeneBank database with fold changes in the steady state mRNA levels at 8 h or at day 4 were imported into the programs and the top-ranking pathways were identified.

Quantitative real-time RT-PCR and data analysis

To validate relative expression levels of selected genes from microarray studies, quantitative real-time RT-PCR (qPCR) was performed using an Applied Biosystems Prism 7700 Sequence Detection System with SYBR Green PCR Master Mix (Applied Biosystems, Inc., Foster City, CA, USA). Primers for qPCR were designed using either the Oligonucleotide Properties Calculator at www.basic.northwestern.edu/biotools/oligocalc.html or the Primer Express (Version 2.0) from Applied Biosystems, Inc. and were compared with the existing database at GenBank using the basic local alignment search tool (BLAST) to ensure specificity (see Table 1). Briefly, total RNA from different samples were prepared using TRIZOL (Invitrogen) and treated with DNaseI (Invitrogen) to remove contaminating genomic DNA before reverse transcription. Equal amount of total RNA was then reverse transcribed using Moloney murine leukemia virus reverse transcriptase (M-MLV RT, Promega) with 2 µg RNA in a 25 µl reaction. Both primers (5 pmol each) and various templates (serially diluted control testis cDNA for generating the standard curve, and 1 µl Reverse transcription product from all samples) were mixed with 2×SYBR Green PCR Master Mix in a 25 µl final reaction volume. The thermal cycler conditions were 10 min at 95 °C, followed by two-step (15 s at 95 °C and 1 min at 60 $^{\circ}$ C) PCR for 40 cycles, and a slow heating up to 95 $^{\circ}$ C for dissociation analysis at the end to ensure the purity of the PCR product. Amplification datawere analyzed with an Applied Biosystems Prism Sequence Detection Software (Version 2.1). The cycle threshold (C_T) value corresponding to the PCR cycle number at which fluorescence emission in real time reached a threshold above the baseline emission was determined. The $C_{\rm T}$ value for each sample was then exported and analyzed in Microsoft Excel. A combination of standard curve and comparative $C_{\rm T}$ methods were applied for the analysis (User Bulletin #2 ABI PRISM 7700 Sequence Detection System, Applied Biosystems). For standard curve method, CT for Stat3 and S-16 were plotted as C_T value against logarithm of relative input RNA amount respectively,

and then the input RNA amount for each sample was calculated based on its $C_{\rm T}$ value in reference to the corresponding standard curve. Relative expression of Stat3 was normalized to the S-16 control for each sample. For comparative $C_{\rm T}$ method, the difference of $C_{\rm T}$ between the target gene and S-16 for each sample was calculated ($\Delta C_{\rm T}$) and then this difference for other samples was compared with that of a particular sample ($\Delta \Delta C_{\rm T}$). The expression level in any sample relative to that particular sample was given by $2^{-\Delta\Delta CT}$. All reactions were prepared in triplicate and three independent sets of samples were used in each experiment. Results of qPCR were analyzed by one-way ANOVA for multiple comparisons using the JMP IN statistical analysis software package (Version 4, SAS, Inc., Cary, NC, USA).

Immunohistochemistry and immunoblot analysis

Immunohistochemistry (IHC) for selected genes was performed essentially as previously described (Xia & Cheng 2005). Antibodies used in this study were either raised in this laboratory (rabbit anti-testin (Cheng & Bardin 1987), anti-cathepsin L (Lee *et al.* 1986), α_2 -MG (Cheng *et al.* 1990)) or purchased from Zymed-Invitrogen (Carlsbad, CA, USA) (rabbit anti-claudin 3 polyclonal antibody). Immunoblot analysis was performed as described earlier (Xia & Cheng 2005). Testis lysates from samples were prepared and resolved by SDS-PAGE and probed against a panel of antibodies.

Assessing changes in the steady-state mRNA levels of target genes in testes taking into account cellular composition alteration in the seminiferous epithelium following Adjudin treatment – a mathematical model

Adjudin treatment induces massive germ cell depletion from the seminiferous epithelium, with initial loss of elongating/elongate spermatids, to be followed by round spermatids and spermatocytes (Chen et al. 2003; Fig. 1A-C). As such, the cellular composition in the epithelium changes with time following treatment, particularly between days 1 and 4, during germ cell sloughing. For instance, if a protein is exclusively expressed by Sertoli cells, such as occludin, its induction that was detected by RT-PCR and/or immunoblotting following Adjudin treatment versus controls by day 4 may simply reflect an increase in cellular RNAs or proteins contributed by Sertoli cells in the samples being analyzed because of declining germ cell numbers as a result of germ cell loss. This thus makes it difficult to assess if induction of a target protein is in fact related to junction restructuring or the result of cellular composition alteration. Herein, we provide a mathematical model to relate changes in cellular composition and an alteration of expression level of a target protein/gene so as to provide a threshold by which one can accept or reject data generated in this Adjudin or similar animal models. Because non-germ cell types in the testis (e.g. Sertoli, Leydig, and myoid cells) do not have any significant changes after Adjudin treatment (Cheng et al. 2001, 2005, Grima et al. 2001), we collectively assigned these cell types as somatic cells and categorized them under the Sertoli cell item as an entity. We also did not discriminate germ cells at different developmental stages and categorized them under the 'germ cell' as an entity. This model was being used to screen target proteins/genes that are pertinent to junction restructuring by accepting their induction in the microarray experiments as physiologically relevant.

We assume the testis weight before Adjudin treatment to be 1 and after treatment to be m, m < 1.

Control (normal) testis status (A) is: p+q=1Testis status after Adjudin treatment (B) is: p'+q'=m where p, p' are the corresponding Sertoli cell fractions before and after Adjudin treatment, and q, q' are the corresponding germ cell fractions before and after Adjudin treatment (assuming p = p' since Sertoli cells were not affected by Adjudin; and $0 , <math>0 < q' \le m$, q > q').

For a target gene of interest, such as Z, its expression level in A (total) is:

 $Z_{A} = p\alpha + q\beta;$

and Z expression level in B (total) is:

 $Z_{\rm B} = p'\alpha' + q'\beta' = p\alpha' + q\beta'$

where α , α' are the corresponding expression coefficients for gene *Z* in Sertoli cells before and after Adjudin treatment in A or B, and β , β' are the corresponding expression coefficients for gene *Z* in germ cells and after Adjudin treatment in A or B with $0 \le \alpha$, α' , β , β' . The expression coefficient of a target gene is the total number of copies of gene *Z* mRNA in Sertoli (α) or germ (β) cells. For instance, in normal testes occludin is expressed in Sertoli cells only. Therefore, α_{occludin} is a positive value and $\beta_{\text{occludin}} = 0$ (note: the exact value for α_{occludin} is not required for the following calculations, see below).

From the microarray experiments, changes in the expression level of a target gene Z for testis status B versus control status A were determined as x. Because the same amount of total RNA has used in treatment versus control samples, i.e. from the same unit weight of testis tissue (assuming the same unit weight of tissue from different samples contain the same amount of total RNA), the following formula was used:

$$Z_{\rm B}/Z_{\rm A} = (p\alpha' + q\beta')/(p\alpha + q\beta) = (x/1) \times (m/1)$$

= $xm/1 \times 1 = mx$

We consider the following three possibilities regarding target gene/protein changes during Adjudin-induced germ cell loss from the seminiferous epithelium:

- If gene Z is only expressed in Sertoli cells: β=0, β'=0. Thus, Z_B/Z_A = α '/α=mx. For example, 4 days after Adjudin treatment, m (weight of testis versus control) =0.73 (see Fig. 1Ad), then if α '/α>1, x should be >1/0.73→x≥1.4. This indicates only those genes with ≥1.4-fold of change are considered to be induced in the testis after Adjudin treatment. We set the threshold x≥2, thus α '/α=mx≥0.73×2≈1.5. For genes listed in Table 4, the threshold is actually x≥4 by day 4, meaning α '/α≥0.73×4≈3.
- 2. If gene Z is only expressed in germ cells: $\alpha=0$, $\alpha'=0$ Thus,

$$\frac{Z_{\rm B}}{Z_{\rm A}} = \frac{(q'\beta')}{(q\beta)} = mx \rightarrow \frac{\beta'}{\beta} = mx\frac{q}{q'} = mx\frac{(1-p)}{(m-p)}$$
$$= x\frac{(m-mp)}{(m-p)} > x$$

(since m < 1).

In this case, the actual fold changes in gene induction in germ cells are greater than the reported fold of changes for *x*.

3. If gene *Z* is expressed in both Sertoli and germ cells:

$$\frac{Z_{\rm B}}{Z_{\rm A}} = \frac{(p\alpha' + q'\beta')}{(p\alpha + q\beta)} = mx$$

Herein,

 $\min[(p\alpha')/(p\alpha), (q'\beta')/(q\beta)] \le (p\alpha'+q'\beta')/(p\alpha+q\beta)$ $\le \max[(p\alpha')/(p\alpha), (q'\beta')/q\beta)]$

where min $[(p\alpha')/(p\alpha), (q'\beta')/(q\beta)]$ is the minimal value of the two and max $[(p\alpha')/(p\alpha), (q'\beta')/(q\beta)]$ is the maximal value of the two (this is because $p\alpha', q'\beta', p\alpha$ and $q\beta$ are all positive values. When $a, b, c, d>0, (a/c) \le (b/d)$, then $(a/c) \le (a+b)/(c+d) \le (b/d)$. Therefore, either $(p\alpha')/(p\alpha) \ge mx$ or $(q'\beta')/(q\beta) \ge mx$.

When we select the threshold for *x* such that $mx \ge 1$ (at day 4, $x \ge 2$ and $mx \ge 1.46$), then either $pa'/pa \ge mx > 1$ ($\rightarrow a'/a \ge 1$, i.e. induction in Sertoli cells) or $q'\beta'/q\beta \ge mx > 1$ ($\rightarrow \beta'/\beta \ge q/q' > 1$, i.e. induction in germ cells). On the other hand, the possibility in (3) can be treated as a mixture of (1) and (2), and on average, Z_B/Z_A should be between the values in (1) and (2) as well. Whichever the possibility, the threshold $x \ge 2$ translates into a minimal 1.5-fold induction in either germ or Sertoli cells. Table 4 lists those target genes with fourfold of induction ($x \ge 4$) by day 4 showing Adjudin treatment, which translates into a minimal threefold of induction in either germ or Sertoli cells.

We selected target gene *Myd116* for the sake of discussion, which was shown to be induced 3.5-fold at 8 h and 1.7-fold at day 4 (see Table 3). At 8 h, $3.5 \times 0.9 = 3.15$ and at day 4, $1.7 \times 0.73 = 1.241$. These results indicate that (1) if this gene is exclusively expressed in Sertoli cells (case 1), there was a 3.15-fold induction at 8 h (significant) and only 1.241-fold induction at day 4 (not likely to be significant); (2) if this gene is exclusively expressed in germ cells (case 2), there was more than 3.5-fold induction at 8 h (significant) and more than 1.7-fold induction at day 4 (not certain); (3) if this gene is expressed both in Sertoli and germ cells (case 3), there was an overall 3.15- to 3.5-fold induction at 8 h (significant) and 1.241- to 1.7-fold induction at day 4 (not certain). Collectively, this gene is significantly induced at 8 h and not likely to be induced significantly at day 4 under all possibilities. Thus, the twofold threshold is a reliable filter to accept or reject any data to assess if a target gene has been induced. Nonetheless, additional cautious steps have to be taken since these data should be validated by techniques of IHC, fluorescent microscopy, and immunoblottings.

Results

Microarray data deposition

The original data sets generated in this report have been deposited at the Gene Expression Omnibus (GEO) data repository website: http://www.ncbi.nih.gov/geo/ with accession number: GSE5131.

Adjudin-induced morphological changes in adult rat testes

The rationale of selecting the 8-h and 4-day time points post-Adjudin treatment for their comparison with control (normal testes) was based on an earlier report that investigated the kinetics of germ cell loss from the epithelium (Chen *et al.* 2003). By 8 h after Adjudin treatment, while more than half of the seminiferous tubules examined (n=600 from four testes with ~125 tubules randomly scored per testis) displayed signs of germ cell loss with ≥ 10 elongating/ elongate spermatids found in tubule lumen, most elongating spermatids, round spermatids, and

spermatocytes still remained attached to Sertoli cells in the epithelium (see Fig. 1Ab vs Fig. 1Aa). This observation also illustrates that even though there was extensive restructuring at the Sertoli-germ cell interface and depleting elongating/ elongate spermatids were found in the lumen, the cellular composition as well as RNAs contributed by Sertoli and germ cells in the samples being analyzed by microarrays were similar to control testes. This argument is supported by the finding that only a $\sim 10\%$ decline, which was not statistically significant, in testicular weight was detected by 8 h (see Fig. 1Ad). By 4 days after Adjudin treatment, about 80% of the tubules that were scored were shown to have the number of round spermatid layers reduced by twofold or more with virtually all elongating/ elongate spermatids depleted from the epithelium, and most of the tubules were only populated with round spermatids, spermatocytes, and spermatogonia along with Sertoli cells (Chen et al. 2003; Fig. 1Ac vs Fig. 1Aa, and b). These results were consistent with a significant loss of testicular weight, by ~27% at day 4 (Fig. 1Ad). Due to the changes in cellular composition in the tubules as a result of progressive germ cell loss, we sought to correct the expression levels of genes detected by microarray studies by normalizing the results by the testis weight loss since total RNA from whole testes was used for microarrayanalysis. In our analysis, a threshold was set at twofold, which translated into ~1.5-fold of net changes $(2 \times 73\%)$ for 4-day samples and ~1.8-fold of net changes $(2 \times 90\%)$ for 8-h samples, so as to set the basis to 'accept' that a target gene had been 'induced' following Adjudin treatment. A detailed quantitative mathematical analysis of gene expression/protein level changes in concert with cellular composition alteration in the seminiferous epithelium is described in Materials and Methods. Based on this analysis, a twofold induction of a target gene/protein expression has exceeded the threshold that could be simply accounted for by cellular composition alterations in the epithelium by 8 h 4-day post Adjudin treatment, which would translate into, at the maximum, a 1.5-fold change for a target gene. As such, the focus of this study was placed on genes that were induced by twofold or more in particular by day 4. As expected, many genes appeared to be down-regulated in 4-day samples when most germ cells were depleted from the epithelium, illustrating that these genes were exclusively or abundantly expressed by germ cells. As such, these data (see Supplementary Table 1 and raw data deposited at GEO website), also offer the means to identify germ cell-specific genes.

Assessment of microarray data

The Affymetrix GeneChip uses external RNA controls, also known as spikes, or spike-in controls, to assess the inter-microarray experimental variations (Bakel & Holstege 2004, Stoughton 2005). Statistical analysis was performed by comparing data obtained from normal (control) rat testes versus treatment groups by one-way ANOVA for multiple comparisons with multiple test correction (default option), and multiple test correction was set to 'none' using the GeneSpring software (see Materials and Methods). The signals for these controls, as well as for housekeeping genes (e.g. glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and β -actin) were consistent between chips (i.e. between different samples) in a single experiment, and were also consistent between samples from different experiments. For testis samples from control rats (n=3) and 8 h (n=2) after Adjudin treatment, about 55% of 31 099 probe sets were positively detected (i.e. present), about 500 (~1.6%) were absent and 44% probe sets were detected as marginal, (Fig. 1Ae). However, samples from rats on day 4 (4 days, n=3) after Adjudin treatment have shown an increase in the number of genes present (~59%), and a reduction in the number of genes marginal (~40%), whereas the number of genes that were absent remained unchanged at ~1.6% (Fig. 1Ae). These results indicated that ~4% of genes in the rat genome or ~1240 probe sets became detectable following a longer period of Adjudin treatment (by day 4) and when the epithelium was devoid of virtually all elongating/elongate spermatids, and $\sim 40-50\%$ round spermatids and $\sim 10-20\%$ spermatocytes (see Fig. 1A). Indeed, an examination of all probe sets by plotting the normalized expression levels at 8 h or at day 4 versus their corresponding raw expression levels or signal intensities in control samples

revealed a more dispersed distribution for day 4 than 8 h (Fig. 1Af vs g). In particular, there were more probe sets at day 4 than at 8 h that fell above or below the twofold threshold lines with signal intensities >100, indicating more genes were differentially regulated at the later time point after Adjudin treatment. We filtered out 1466 transcripts which were significantly regulated after Adjudin treatment (control, 8 h and day 4) by one-way ANOVA. There were many more transcripts that were up- or down-regulated by at least twofold in 4-day samples than in 8 h samples (Fig. 1B), consistent with the data shown in Fig. 1Af and g. There were 79 transcripts showing more than twofold change in expression; within this group, 31 had more than twofold change detectable only at 8 h but not at day 4, 48 transcripts were regulated by more than twofold both at 8 h and at day 4 (Fig. 1B). However, 436 transcripts showed more than twofold change only at day 4 but not at 8 h (Fig. 1B). Selected genes belonging to these three categories (>twofold change at 8 h only; >twofold change at day 4 only; and >twofold change at both time points) are summarized in Tables 3-5. Table 4 summarizes the partial list of 436 transcripts with more than fourfold induction. The full list can be found in Supplementary Table 1 (see supplementary data in the online version of the Journal of Endocrinology at http://joe.endocrinology-journals.org/content/vol192/issue3/).

Since many genes related to junction remodeling have previously been studied in the Adjudin model either by RT-PCR or by immunoblotting, a comparison of the expression levels of selected target genes from these experiments versus the results of microarray experiment could assess the reliability of these microarray data. Such genes are tabulated in Table 2. Indeed, these microarray data illustrated that they reproduced or recaptured the expression alterations of these target genes earlier reported from this laboratory. For instance, testin was shown to be induced drastically at day 4 with at least 6- to 15-fold and ~50-fold increase in protein and mRNA levels when detected by RIA and northern blots respectively (Grima *et al.* 2001,Xia & Cheng 2005), and there was an almost 50-fold increase in mRNA level detected by microarray as shown in Table 2. Other target proteins, such as N-cadherin, β 1-integrin, and TGF- β 3, also yielded consistent results between microarray and earlier RT-PCR and immunoblot data (Table 2).

Expression profiling of the Adjudin-induced germ cell depletion model based on microarray: data validations by quantitative real-time PCR (qPCR), immunoblotting (IB), and immunohistochemistry (IHC)

Genes with more than twofold change in their expression levels were tabulated and grouped by their general functions (Tables 3–5). Among these are cytokines, transcription factors, kinases, phosphatases, genes that regulate ion homeostasis and transport, proteases, protease inhibitors, cell adhesion molecules, and signaling molecules. These tables listed the top-ranked genes from classifications defined in Fig. 1B and these top-ranked genes fell into the aforementioned functional groups, indicating these genes are likely involved in the event of germ cell depletion from the seminiferous epithelium induced by Adjudin.

In the cytokine group, interleukin (IL) and chemokines are most common in early and late time points after Adjudin treatment. IL-1 α and Cxcl10 showed strong induction by 8 h, but their expression level receded by day 4 (Table 3). Cxcl12 and Il17re were only induced by day 4 (Table 4). Cxcl1, Ccl2, and Cx3cl1 showed consistent up-regulation at both time points (Table 5).

A number of transcription factors were significantly induced after Adjudin treatment. Some were induced mostly at 8 h, which included Egr1 and Egr2, Bhlhb2, and Jun (Table 3). At day 4, Nupr1 and Pawr became significantly up-regulated versus control (Table 4). Transcription factors, Myc, Stat3, Atf3, and c-fos, also showed strong induction at 8 h and at day 4 (Table 5). Transcription factors that were induced during Adjudin-induced germ cell loss from the testis as shown in Tables 3–5 were summarized in Table 6 along with their known function in

the testis, illustrating these may be potential regulators of junction restructuring events at the Sertoli–germ cell interface, pertinent to spermatogenesis.

Only a few genes displayed more than twofold reduction in their expression levels by 8 h after Adjudin treatment, and these include *Camk2g*, *Th*, and *Btbd14b* (Table 3). The number of genes showing a reduced expression by 8 h or 4 days after Adjudin treatment was considerably less than those displaying an increase in their expression (Tables 3–5, Supplementary Table 1).

We selected a number of target genes to validate their expression changes detected by microarray using other methods as follows: (1) transcription factors: Stat3, Jun, Bhlhb2, and c-fos (Fig. 2A and B); (2) cytokines and related molecules: IL-1 α , Cxcl10, and Tnfrsf1a (Fig. 2C); and (3) proteases and protease inhibitors: Prss11 and Serping1 (Fig. 2D). The fold changes determined by qPCR were consistent with microarray data for all nine genes selected for analysis (Fig. 2 vs Tables 3–5). For instance, both Prss11 and Serping1 showed relatively little change at 8 h but were induced by about four- to fivefold at day 4 (Table 4) in microarray analysis, and results from qPCR showed that at 8 h, the steady-state mRNA levels of these two genes were not significantly different from controls but were induced by approximately fivefold at day 4 (Fig. 2D). Since these nine genes were randomly selected from Tables 3–5 for analysis, it is logical to conclude that the fold change detected for other genes listed in these tables is reliable. Furthermore, the changes in the steady-state mRNA levels of cytokines reported in Tables 3–5, such as Cxcl1, were confirmed using cytokine antibody array (data not shown).

Several additional target genes that were or were not listed in the tables were also selected, and changes in their protein levels were examined by IB and IHC. The cathepsin L (Ctsl) steadystate mRNA level was shown to be induced by 2.5- and 3.1-fold by 8 h and 4 days respectively, by microarray (Table 5). Consistent with these findings, the cathepsin L protein level was shown to be stimulated by approximately two- and fivefold by 8 h and 4 days respectively, by IB analysis (Fig. 3Aa). The signals were also shown to be stimulated in IHC (Fig. 3Ab, c and d). α_2 -Macroglobulin (α_2 -MG) was found to be induced by 1.1-fold at 8 h and threefold at day 4 (Supplementary Table 1), and this pattern of induction was consistent with the IB and IHC data (Fig. 3B). The testin steady-state mRNA level was induced by approximately twofold at 8 h and ~50-fold at day 4 (Tables 2 and 5), with its protein level induced by approximately sixfold at day 4 (Table 2 and Fig. 3Ca). These results are also consistent with data obtained by IHC (Fig. 3Cd versus Fig. 3Cbc). Changes in the expression of a tight junction integral membrane protein, claudin 3, were also examined. For example, claudin 3 displayed no change in protein level and distribution after Adjudin treatment (Fig. 3D). These results were consistent with microarray data, which showed no significant changes on claudin 3, claudin 1, and occluding after Adjudin treatment (data not shown; see raw data in GEO depository). However, other tight junction (TJ) proteins displayed significant changes at day 4. For instance, JAM-A and claudin 11 showed a ~1.8-fold increase in expression at day 4 (but no change at 8 h), and claudin 4 expression level was reduced by as much as 50% at day 4 (data not shown; see raw data in GEO depository). These results also illustrate the expression of different TJ proteins were differentially regulated.

Clustering analysis to identify genes that are closely regulated

We performed unsupervised hierarchical clustering of the eight samples (Ctrl (n=3), 8 h (n=2), and day 4 (n=3)) and the 1466 transcripts using the GeneSpring software and the results were summarized in Fig. 4. The branches of the dendrogram were removed from this presentation, but the main subtrees were illustrated by a line showing five different domains (Figure 4a–e), which were again classified into two larger subtrees of i and ii. This clustering analysis grouped similarly regulated genes. Two representative regions in the dendrogram were selected and examined in detail in Fig. 4B and C, which showed the induced expression of these genes at

day 4 but not at 8 h, and reduced expression at 8 h but mildly increased expression at day 4 respectively.

Identifying and ranking signaling pathways activated by Adjudin in the testis

We next used Pathway Express (PE) to identify the signaling pathways that were activated during Adjudin-induced germ cell loss from the epithelium (Draghici et al. 2003a,b, Khatri et al. 2004, 2005; Table 7). PE is a tool in the Onto-Tools ensemble (Wayne State University, see http://vortex.cs.wayne.edu (Draghici et al. 2003a,b, Khatri et al. 2004, 2005)) that was designed to identify the signaling pathways that contain the corresponding target genes. A list of genes with their fold changes were first submitted to the system, which then performed a search and built a list of all associated pathways. The system calculated an impact factor to rank the pathways based on the importance of a gene in the pathway (indicating how much it affects the downstream signaling), the strength or fold of change of the gene, and percentage of genes in the pathway that were included in this list of genes (Khatri et al. 2004, 2005). The probe set ID number with the corresponding fold changes at 8 h or at day 4 were tabulated (all 1466 probe sets) and imported into the program and the top signaling pathways were identified. At 8 h, the top-ranking pathways identified based on the impact factor were phosphatidylinositol (PI) signaling (7/43: input genes/pathway genes), focal adhesion (13/109), cytokine-cytokine receptor interactions (16/110), MAPK signaling pathway (21/153), tight junction (10/185), apoptosis (11/66), and calcium signaling pathway (13/161); Table 7). At day 4, the top-ranking pathways were phosphatidylinositol signaling, focal adhesion, cytokine-cytokine receptor interactions, tight junction, MAPK signaling pathway, apoptosis, and calcium signaling pathway (Table 7). The numbers of input and pathway genes for 8 h and day 4 were the same. Collectively, these results were consistent with recently published findings that these are putative signaling pathways that regulate Sertoli-germ cell adhesion (Lui et al. 2003a, Siu et al. 2003b, 2005, Wong et al. 2005, Xia & Cheng 2005, Zhang et al. 2005) and probably suggest that these are the most important signaling events taking place in the testis after the rats were treated with Adjudin.

Discussion

Junction restructuring during spermatogenesis is a complex process regulated by a multitude of molecules

This microarray study has identified genes that are differentially regulated during Adjudininduced AJ restructuring at the Sertoli–germ cell interface prior to the massive physical dislodging of germ cells, at 8 h vs day 4, when virtually all elongating/elongate spermatids and most round spermatids and spermatocytes were depleted from the epithelium, and compared with normal testes. Among these genes, we summarize those with most drastic induction in the steady-state mRNA level versus controls and categorize them into functional groups (Tables 3–5). Although only the expression data were obtained using this genome-wide gene profiling approach without considering translational and post-translational regulations, these genes nonetheless are potentially key players in the junction restructuring events at spermatogenesis since recent studies using specific inhibitors and the other models involving steroid implants to suppress endogenous testosterone level in the testis have clearly demonstrated that data obtained from this model is relevant to the in vivo physiology of Sertoligerm cell interactions, particularly cell adhesion regulation (Lui et al. 2003a, Siu et al. 2003b,2005,Siu & Cheng 2004,Lee & Cheng 2005,Lee et al. 2005,Wong et al. 2005,Xia & Cheng 2005). The identified genes include those that are involved in signaling and/or regulatory functions pertinent to the junction restructuring: (1) cell-cell communication, including cytokine-mediated signaling, ion transport and homeostasis; (2) intracellular signaling mediated via kinases, phosphatase, and adaptors; (3) structurally important cell adhesion and cytoskeleton-related proteins; (4) proteases and protease inhibitors that affect cell matrix, cell-

cell and intracellular interactions; and (5) transcription factors. Except for the last group and ion transport/homeostasis proteins, genes belonging to all other groups have been investigated and shown to be involved in regulating junction restructuring in earlier studies (Mruk & Cheng 2004b). We had since proposed a junction restructuring theory to describe the mechanisms of germ cell movement in the seminiferous epithelium (Mruk & Cheng 2004b). This theory was formulated based on studies of in vivo (e.g. Adjudin model, cadmium model), and in vitro (e.g. Sertoli-germ cell co-cultures) which have also identified several putative signaling pathways that are known to regulate Sertoli-germ cell adhesion (Lui et al. 2003a, Siu et al. 2003b, Lee et al. 2005), which are also confirmed in this microarray study. Perhaps the most important of all, results of this gene profiling study have unraveled two important lines of research pertinent to Sertoli-germ cell adhesion regulation. First, additional mechanistic pathways that can be potentially crucial to Sertoli-germ cell adhesion have been identified. For instance, this gene profiling study has demonstrated that PI-3 kinase, FAK, and MAPK are the leading signaling molecules that are involved in the Adjudin-induced Sertoli-germ cell AJ restructuring, confirming results of earlier studies (Lui et al. 2003a, Siu et al. 2003b, 2005, Wong et al. 2005, Xia & Cheng 2005, Zhang et al. 2005, Xia et al. 2006). However, cytokine-cytokine receptor interactions, besides TGF- β 3, TNF α , and their corresponding receptors, IL-1 α and its receptors, have been identified to be a crucial mechanism to AJ dynamic regulation. This suggests that an array of cytokines produced by Sertoli and germ cells into the microenvironment at the seminiferous epithelium such as the blood - testis barrior, are working in concert to activate their receptors in tandem to regulate junction restructuring events pertinent to spermatogenesis. Furthermore, the calcium signaling pathway and apoptosis regulatory genes are both activated, which should be carefully evaluated in future studies. Secondly, a set of transcription factors have now been identified, some of which can potentially regulate TJ and/or AJ dynamics, which should be carefully evaluated in future studies. It will also be crucial in future studies to examine if the downstream action of PI-3 kinase, FAK, and MAPK are mediated via one or several of these transcription factors.

Does the Adjudin model reveal physiologically relevant information on the biology of spermatogenesis?

Besides building expression profiles of thousands of genes in the testis, results from this microarray study could be used to identify genes pertinent to other testicular function. Indeed, many transcripts were found to be significantly induced after multiple rounds offiltering. We did not explore the potential functions of these 'new' genes in this study but they are summarized in Supplementary Table 2

(http://joe.endocrinology-journals.org/content/vol192/issue3/). At present, a number of expression profile studies in the testis are available in the literature (Schlecht *et al.* 2004, Small *et al.* 2005, Zhou *et al.* 2005) pertinent to development, spermatogenesis, and/or fertility regulation. The present study, however, uses an exogenic compound and examines its effect in the testicular gene expression during the time course of germ cell loss with extensive restructuring at the Sertoli–germ cell interface. An important question remains to be addressed: does this drug model reveal the molecular targets pertinent to spermatogenesis?

The approach of using the Adjudin model to identify molecular targets pertinent to junction remodeling during spermatogenesis may be criticized that the changes in the expression of multiple genes are the results of drug toxicity. However, recently completed toxicity studies have shown that the dose used in the present study that was effective to induce germ cell loss had no toxic effects in rats or mice (Cheng *et al.* 2005, Mruk *et al.* 2006). Moreover, Adjudin-induced germ cell depletion is reversible (Cheng *et al.* 2001, Grima *et al.* 2001). The Adjudin effects on a number of genes seemingly support the notion that this model offers a snapshot of expression alterations that represent their changes during spermatogenesis. For instance, cathepsin L becomes highly expressed at stages VII–VIII (Erikson-Lawrence *et al.* 1991,

Anway *et al.* 2004), which coincides with spermiation and BTB restructuring, and is also induced during Adjudin-induced germ cell loss from the epithelium, mimicking the cellular events of spermiation. TGF- β 3, which was shown to disrupt both Sertoli–germ cell adhesion and BTB integrity and was known to be stage-specifically regulated with the highest expression at stages VI–VIII (Xia & Cheng 2005, Xia *et al.* 2006), is also induced after Adjudin treatment at the time of germ cell loss, possibly because of AJ restructuring and this observation is consistent with the results of an earlier report (Xia & Cheng 2005).

Thus, we hypothesize that the Adjudin-induced restructuring at the Sertoli-germ cell interface mimics the anchoring junction restructuring events in the epithelium during spermatogenesis. This postulate was supported by recent findings that the signaling molecules crucial to Sertoli– germ cell AJ dynamics as identified using the Adjudin model, such as p-FAK, p-c-Src, rMTMR2, and pERK (Li et al. 2000, Siu et al. 2003b, 2005, Xia & Cheng 2005) have also been found in another in vivo model using androgen/estrogen implants to suppress the intratesticular androgen level which is known to perturb Sertoli-spermatid adhesion in adult testes (O'Donnell et al. 2000, Wong et al. 2005, Xia et al. 2005b, Zhang et al. 2005). This is plausibly due to the fact that there are only a limited number of signaling pathways and molecular mechanisms that control a specific phenotype. For instance, if classified by the types of cell surface receptors involved, the number of signaling pathways in human cells can be as small as 16, and as many as 200 only if counting all the variants of receptors (Fishman & Porter 2005). Normal spermatogenesis and the Adjudin-induced germ cell depletion model share some phenotypic features, such as junction restructuring, and it is not unusual that they utilize similar signals and/or regulatory mechanisms. This hypothesis should be carefully evaluated in future studies. Likewise, results using Pathway Express to rank the top signaling pathways that were activated by Adjudin in testes also support this postulate. Lipid and protein kinases, such as PI-3 kinase, are important transducers to relay signals from matrix to cells, regulating cytoskeletal remodeling, and cell migration (Carragher & Frame 2004, Webb et al. 2004). It is not surprising to find that phosphatidylinositol signaling and focal adhesion kinase signaling were the top two pathways. Indeed in studies using the Adjudin model, Sertoli-germ cell cocultures, and the androgen-suppression model have shown that integrin β 1, PI-3 kinase, and its downstream protein kinases are crucial regulators of restructuring at the apical ES (Siu et al. 2003b, 2005, Wong et al. 2005). Additionally, MAPKs have also been identified in earlier studies as important regulators of junction dynamics in the testis (Lui et al. 2001, 2003b,c, Wong et al. 2004, Wong & Yan Cheng 2005, Xia & Cheng 2005, Xia et al. 2005a, 2006). Taken collectively, these results provide strong evidence that the Adjudin model is useful to study the junction restructuring events pertinent to spermatogenesis.

Molecular signatures for the regulation of junction restructuring during spermatogenesis

It is of interest to note that junction restructuring and migration of different cell types share similar underlying regulatory mechanisms, since these events are fundamentally conserved across species and cell types regarding the molecules that are involved in these cellular processes. For instance, results from this study have pinpointed the important players in these events in the testis (Tables 3–5). Unsurprisingly, these results were in agreement with other genomic-scale profiling studies which have also identified genes belonging to kinases, proteases, cell adhesion molecules, and cytokine signalings are enriched in migratory cells (Borghese *et al.* 2006, Wang *et al.* 2006). We herein discuss target gene groups identified in this Adjudin model, which may be crucial to junction remodeling during germ cell migration.

Cytokines and cytokine receptor signalings

Besides TGF- β 3 (Xia & Cheng 2005), Adjudin indeed activated the expression of several cytokines and chemokines in adult rat testes. ILs and chemokines are typically involved in inflammatory responses and they are also crucial to T-cell migration (Petersen *et al.* 2006).

Other studies have shown that cytokines are important players of immunological responses in the testis after stress or injury (Hedger & Meinhardt 2003). However, as no macrophage infiltration in the testis was observed after Adjudin treatment, it is logical toconclude that the inflammationresponse to Adjudin is probably a negligible possibility. The activation of multiple cytokines and chemokines at the time of germ cell loss implies that these paracrine/ autocrine factors are involved in the signaling cascades that lead to the restructuring at the Sertoli–germ cell interface. For instance, IL-1 α is a pro-inflammatory cytokine but in the testis it is also secreted by Sertoli cells in the absence of local inflammation (Sultana *et al.* 2004). An IL-1 α isoform was found to be secreted bidirectionally to the interstitium and intratubular compartment (Sultana *et al.* 2004). As a paracrine factor, it regulates Leydig cell steroidogenesis with age-dependent effects (Sultana *et al.* 2004). By 8 h after Adjudin treatment, a drastic induction (8.6-fold) of IL-1 α was detected, which strongly suggests that its early response signifies its significance in AJ restructuring, which should be investigated in future studies.

Cx3cl1 (or fractalkine) is also expressed in Leydig cells, Sertoli cells, and spermatogonia and it is believed to be regulating cell–cell interactions in and out of the seminiferous tubules and other epithelia (Rossi *et al.* 1998, Habasque *et al.* 2003). In the Adjudin model, a 3.2- and 5.3fold increase in expression at 8 h and at day 4 respectively, were detected. Vgf (VGF nerve growth factor inducible) was found to be highly induced after Adjudin treatment (3- and 16fold increase at 8 h and at day 4 respectively), although its basal expression level in the rat testis was relatively low (raw signal intensity at ~30). There is no literature on Vgf in the testis, since Vgf is a neuron-secreted polypeptide, particularly abundant in adult hypothalamus. $Vgf^{-/-}$ mice were found to be small, hypermetabolic, hyperactive, and infertile for both males and females (Hahm *et al.* 1999), which is likely the result of a reduced production of pituitary gonadotropin hormones (Hahm *et al.* 1999), which in turn, affected spermatogenesis in the testis. In short, these cytokines should be examined closely to determine if they play any role in Sertoli–germ cell AJ restructuring during spermatogenesis.

Proteases and protease inhibitors

Cathepsin L and tissue-type plasminogen activator (tPA) are known to be expressed stage specifically in the testis (Vihko *et al.* 1989, Chung *et al.* 1998). Cathepsin L and urokinase-type plasminogen activator (uPA) are also induced in the cadmium model (Wong *et al.* 2004), supporting the notion that they take part in the regulation of junction restructuring. Similarly, tissue inhibitor of metalloproteases 1 (TIMP-1) was also found to regulate BTB and AJ dynamics (Mruk *et al.* 2003, Siu *et al.* 2003*a*), but its activation in the Adjudin model has not been reported until now (see Table 4). The function of other proteases and protease inhibitors, such as *Prss11* and *Serping1*, in these events are not known. For instance, no reports are found in the literature regarding the expression of *Spin2c* or *Serping1* by the testis, but they are highly induced after Adjudin treatment (Table 4). It will be of interest to examine the regulation of these proteins in the testis during the epithelial cycle and their role in AJ restructuring.

Transcription factors

Transcription factors that were induced by Adjudin in the testis were summarized in Table 6. For example, early growth responses 1 and 2 (*Egr1* and *Egr2*) were greatly induced 8 h after Adjudin treatment (Table 3). They belong to the *Egr* family of zinc-finger transcription factors, which are known to be involved in cellular growth and differentiation (Hofmann *et al.* 2005, Oatley *et al.* 2006). Another gene in the same family, *Egr4* is also essential for spermatogenesis. Male *Egr4* null mice were infertile because most of the germ cells underwent apoptosis at the early-mid pachytene spermatocyte stage (Tourtellotte *et al.* 1999). The

involvement of these transcription factors in junction restructuring in the testis should be closely examined in future studies.

Signaling molecules

A large number of signaling molecules were found to be induced after Adjudin treatment. Although it is still difficult to put them in context with the regulation of cellular events at the Sertoli–germ cell interface, these findings, nonetheless, have provided new leads for future research. For example, *Crim1* (cysteine-rich motor neuron 1) was found to be activated by 2.3-fold at 8 h and 5.9-fold at day 4 (Table 5). *Crim1* was originally identified in the developing nervous systems in vertebrates (Kolle *et al.* 2000). This protein was activated during murine gonad development and expressed strongly in Sertoli cells (Georgas *et al.* 2000). It functions to antagonize bone morphogenic proteins, and possibly TGF- β s (Georgas *et al.* 2000). It is not known if adult testes also express *Crim1* but the signal intensity of *Crim1* detected by microarray was comparable with that of TGF- β 3 in control testes (175 vs 135), indicating *Crim1* indeed is expressed in adult testes. Since TGF- β superfamily genes play essential roles in testicular development and function (Skinner 1993,Gnessi *et al.* 1997,Shimasaki *et al.* 2004,Xia *et al.* 2005*a*), the identification of a new regulator of this superfamily is of great interest in future studies to examine their interacting physiological roles in maintaining spermatogenesis and testicular function.

Summary and conclusion

This microarray profiling study has identified different target genes belonging to several functional groups that may be important for the regulation of junction restructuring during spermatogenesis. Some of these genes highlighted herein merit additional research to delineate their role and involvement in spermatogenesis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Wenxiang Zhang and Dr Xuning Wang at The Rockefeller University Genomics Resource Center (New york, NY, USA) for their excellent technical assistance in the microarray experiments and data analysis. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

Funding

Supported in part by grants from the National Institutes of Health (NICHD, U01 HD045908 and U54 HD029990, Project 3 to C Y C), the CONRAD Program (CICCR, CIG 01-72 to CYC; CIG 01-74 to DDM) and Hong Kong Research Grant Council (HKU 7413/04M and HKU 7536/05M to WML). WX was the recipient of a University of Hong Kong Postgraduate Research Studentship Award.

References

- Alcivar AA, Hake LE, Hardy MP, Hecht NB. Increased levels of junB and c-jun mRNAs in male germ cells following testicular cell dissociation. Maximal stimulation in prepuberal animals. Journal of Biological Chemistry 1990;265:20160–20165. [PubMed: 1700782]
- Anway MD, Wright WW, Zirkin BR, Korah N, Mort JS, Hermo L. Expression and localization of cathepsin K in adult rat Sertoli cells. Biology of Reproduction 2004;70:562–569. [PubMed: 14585819]
- Bakel, Hv; Holstege, FCP. In control: systematic assessment of microarray performance. EMBO Reports 2004;5:964–969. [PubMed: 15459748]

- Borghese L, Fletcher G, Mathieu J, Atzberger A, Eades WC, Cagan RL, Rorth P. Systematic analysis of the transcriptional switch inducing migration of border cells. Developmental Cell 2006;10:497–508. [PubMed: 16580994]
- Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends in Cell Biology 2004;14:241–249. [PubMed: 15130580]
- Chen YM, Lee NPY, Mruk DD, Lee WM, Cheng CY. Fer kinase/FerT and adherens junction dynamics in the testis: an *in vitro* and *in vivo* study. Biology of Reproduction 2003;69:656–672. [PubMed: 12700184]
- Cheng CY, Bardin CW. Identification of two testosterone-responsive testicular proteins in Sertoli cellenriched culture medium whose secretion is suppressed by cells of the intact seminiferous tubule. Journal of Biological Chemistry 1987;262:12768–12779. [PubMed: 3624278]
- Cheng CY, Mruk DD. Cell junction dynamics in the testis: sertoli-germ cell interactions and male contraceptive development. Physiological Reviews 2002;82:825–874. [PubMed: 12270945]
- Cheng CY, Grima J, Stahler MS, Guglielmotti A, Silvestrini B, Bardin CW. Sertoli cell synthesizes and secretes a protease inhibitor, a2-macroglobulin. Biochemistry 1990;29:1063–1068. [PubMed: 1692734]
- Cheng CY, Silvestrini B, Grima J, Mo M-Y, Zhu L-J, Jahansson E, Saso L, Leone M-G, Palmery M, Mruk D. Two new male contraceptives exert their effects by depleting germ cells prematurely from the testis. Biology of Reproduction 2001;65:449–461. [PubMed: 11466213]
- Cheng CY, Mruk D, Silvestrini B, Bonanomi M, Wong C-H, Siu MKY, Lee NPY, Lui W-Y, Mo M-Y. AF-2364 [1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide] is a potential male contraceptive: a review of recent data. Contraception 2005;72:251–261. [PubMed: 16181968]
- Chung SSW, Zhu L-J, Mo M-Y, Silvestrini B, Lee WM, Cheng CY. Evidence for cross-talk between Sertoli and germ cells using selected cathepsins as markers. Journal of Andrology 1998;19:686–703. [PubMed: 9876020]
- Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes and Development 1993;7:671–682. [PubMed: 8458579]
- de Kretser, DM.; Kerr, JB. The cytology of the testis. In: Knobil, E.; Neill, JD., editors. The Physiology of Reproduction. Vol. 2. New York: Raven Press; 1994. p. 1177-1300.
- Draghici S, Khatri P, Bhavsar P, Shah A, Krawetz SA, Tainsky MA. Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Research 2003a;31:3775–3781. [PubMed: 12824416]
- Draghici S, Khatri P, Martins RP, Ostermeier GC, Krawetz SA. Global functional profiling of gene expression. Genomics 2003b;81:98–104. [PubMed: 12620386]
- Eddy EM. Regulation of gene expression during spermatogenesis. Seminars in Cell and Developmental Biology 1998;9:451–457. [PubMed: 9813192]
- Erikson-Lawrence M, Zabludoff SD, Wright WW. Cyclic protein-2, a secretory product of rat Sertoli cells, is the proenzyme form of cathepsin L. Molecular Endocrinology 1991;5:1789–1798. [PubMed: 1791830]
- Fishman MC, Porter JA. A new grammar for drug discovery. Nature 2005;437:491–493. [PubMed: 16177777]
- Garcia-Cao I, Lafuente MJ, Criado LM, Diaz-Meco MT, Serrano M, Moscat J. Genetic inactivation of Par4 results in hyperactivation of NF-κB and impairment of JNK and p38. EMBO Reports 2003;4:307–312. [PubMed: 12634851]
- Garcia-Montero AC, Vasseur S, Giono LE, Canepa E, Moreno S, Dagorn JC, Iovanna JL. Transforming growth factor β-1 enhances Smad transcriptional activity through activation of p8 gene expression. Biochemical Journal 2001;357:249–253. [PubMed: 11415456]
- Georgas K, Bowles J, Yamada T, Koopman P, Little MH. Characterisation of Crim1 expression in the developing mouse urogenital tract reveals a sexually dimorphic gonadal expression pattern. Developmental Dynamics 2000;219:582–587. [PubMed: 11084657]
- Gnessi L, Fabbri A, Spera G. Gonadal peptides as mediators of development and functional control of the testis: an integrated system with hormones and local environment. Endocrine Reviews 1997;18:541–609. [PubMed: 9267764]

- Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancerselective therapeutic target. Cancer Research 2006;66:2889–2892. [PubMed: 16540633]
- Grima J, Zhu L-j, Cheng CY. Testin Is tightly associated with testicular cell membrane upon its secretion by Sertoli cells whose steady-state mRNA level in the testis correlates with the turnover and integrity of inter-testicular cell junctions. Journal of Biological Chemistry 1997;272:6499–6509. [PubMed: 9045675]
- Grima J, Silvestrini B, Cheng CY. Reversible inhibition of spermatogenesis in rats using a new male contraceptive, 1-(2,4-dichlorobenzyl)-indazole-3-carbohydrazide. Biology of Reproduction 2001;64:1500–1508. [PubMed: 11319158]
- Habasque C, Satie A-P, Aubry F, Jegou B, Samson M. Expression of fractalkine in the rat testis: molecular cloning of a novel alternative transcript of its gene that is differentially regulated by pro-inflammatory cytokines. Molecular Human Reproduction 2003;9:449–455. [PubMed: 12837921]
- Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, Kozak CA, Boozer CN, Peng B, McEvoy RC, Good P, et al. Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 1999;23:537–548. [PubMed: 10433265]
- Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/ cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 2001;273:1–11. [PubMed: 11483355]
- Hartman MG, Lu D, Kim M-L, Kociba GJ, Shukri T, Buteau J, Wang X, Frankel WL, Guttridge D, Prentki M, et al. Role for activating transcription factor 3 in stress-induced β-cell apoptosis. Molecular and Cellular Biology 2004;24:5721–5732. [PubMed: 15199129]
- Hedger MP, Meinhardt A. Cytokines and the immune-testicular axis. Journal of Reproductive Immunology 2003;58:1–26. [PubMed: 12609522]
- Hofmann M-C, Braydich-Stolle L, Dym M. Isolation of male germ-line stem cells; influence of GDNF. Developmental Biology 2005;279:114–124. [PubMed: 15708562]
- Jenab S, Morris PL. Transcriptional regulation of Sertoli cell immediate early genes by interleukin-6 and interferon-γ is mediated through phosphorylation of STAT-3 and STAT-1 proteins. Endocrinology 1997;138:2740–2746. [PubMed: 9202212]
- Johnson RS, Spiegelman BM, Papaioannou V. Pleiotropic effects of a null mutation in the c-fos protooncogene. Cell 1992;71:577–586. [PubMed: 1423615]
- Johnson RS, van Lingen B, Papaioannou VE, Spiegelman BM. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes and Development 1993;7:1309–1317. [PubMed: 8330736]
- Khatri P, Bhavsar P, Bawa G, Draghici S. Onto-Tools: an ensemble of web-accessible, ontology-based tools for the functional design and interpretation of high-throughput gene expression experiments. Nucleic Acids Research 2004;32:W449–W456. [PubMed: 15215428]
- Khatri P, Sellamuthu S, Malhotra P, Amin K, Done A, Draghici S. Recent additions and improvements to the Onto-Tools. Nucleic Acids Research 2005;33:W762–W765. [PubMed: 15980579]
- Koji T, Izumi S, Tanno M, Moriuchi T, Nakane PK. Localization in situ of c-myc mRNA and c-myc protein in adult mouse testis. Histochemical Journal 1988;20:551–557. [PubMed: 2464562]
- Kolle G, Georgas K, Holmes GP, Little MH, Yamada T. CRIM1, a novel gene encoding a cysteine-rich repeat protein, is developmentally regulated and implicated in vertebrate CNS development and organogenesis. Mechanisms of Development 2000;90:181–193. [PubMed: 10642437]
- Lafuente MJ, Martin P, Garcia-Cao I, Diaz-Meco MT, Serrano M, Moscat J. Regulation of mature T lymphocyte proliferation and differentiation by Par-4. EMBO Journal 2003;22:4689–4698. [PubMed: 12970181]
- Lau ASN, Mruk DD. Rab8B GTPase and junction dynamics in the testis. Endocrinology 2003;144:1549–1563. [PubMed: 12639940]
- Lee NPY, Cheng CY. Protein kinases and adherens junction dynamics in the seminiferous epithelium of the rat testis. Journal of Cellular Physiology 2005;202:344–360. [PubMed: 15389520]
- Lee NPY, Mruk D, Lee WM, Cheng CY. Is the cadherin/catenin complex a functional unit of cell-cell actin-based adherens junctions in the rat testis? Biology of Reproduction 2003;68:489–508. [PubMed: 12533412]

- Lee NPY, Mruk DD, Conway AM, Cheng CY. Zyxin, axin, and Wiskott-Aldrich syndrome protein are adaptors that link the cadherin/catenin protein complex to the cytoskeleton at adherens junctions in the seminiferous epithelium of the rat testis. Journal of Andrology 2004;25:200–215. [PubMed: 14760006]
- Lee NPY, Mruk DD, Wong C-H, Cheng CY. Regulation of Sertoli-germ cell adherens junction dynamics in the testis via the nitric oxide synthase (NOS)/cGMP/protein kinase G (PRKG)/β-catenin (CATNB) signaling pathway: an *in vitro* and *in vivo* study. Biology of Reproduction 2005;73:458–471. [PubMed: 15858215]
- Lee WM, Cheng CY, Bardin CW, Gunsalsu GL, Musto NA. Measurement of a follicle-stimulating hormone-responsive protein of Sertoli cell origin using an enzyme-linked immunoblot assay. Endocrinology 1986;119:1914–1921. [PubMed: 3095094]
- Lee SL, Sadovsky Y, Swirnoff AH, Polish JA, Goda P, Gavrilina G, Milbrandt J. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science 1996;273:1219–1221. [PubMed: 8703054]
- Li JCH, Samy ET, Grima J, Chung SSW, Mruk D, Lee WM, Silvestrini B, Cheng CY. Rat testicular myotubularin, a protein tyrosine phosphatase expressed by Sertoli and germ cells, is a potenial marker for studying cell-cell interactions in the rat testis. Journal of Cellular Physiology 2000;185:366–385. [PubMed: 11056007]
- Lim K, Hwang B-D. Follicle-stimulating hormone transiently induces expression of protooncogene cmyc in primary Sertoli cell cultures of early pubertal and prepubertal rat. Molecular and Cellular Endocrinology 1995;111:51–56. [PubMed: 7649352]
- Lim K, Yoo JH, Kim KY, Kweon GR, Kwak ST, Hwang BD. Testosterone regulation of proto-oncogene c-myc expression in primary Sertoli cell cultures from prepubertal rats. Journal of Andrology 1994;15:543–550. [PubMed: 7721656]
- Lui WY, Lee WM, Cheng CY. Transforming growth factor-β3 perturbs the inter-Sertoli tight junction permeability barrier *in vitro* possibly mediated via its effects on occludin, zonula occludens-1, and claudin-11. Endocrinology 2001;142:1865–1877. [PubMed: 11316752]
- Lui WY, Lee WM, Cheng CY. Sertoli-germ cell adherens junction dynamics in the testis are regulated by RhoB GTPase via the ROCK/LIMK signaling pathway. Biology of Reproduction 2003a;68:2189– 2206. [PubMed: 12606349]
- Lui WY, Lee WM, Cheng CY. Transforming growth factor-β3 regulates the dynamics of Sertoli cell tight junctions via the p38 mitogen-activated protein kinase pathway. Biology of Reproduction 2003b; 68:1597–1612. [PubMed: 12606350]
- Lui WY, Wong C-H, Mruk DD, Cheng CY. TGF-β3 regulates the blood-testis barrier dynamics via the p38 mitogen activated protein (MAP) kinase pathway: an *in vivo* study. Endocrinology 2003c; 144:1139–1142. [PubMed: 12639893]
- Mallo GV, Fiedler F, Calvo EL, Ortiz EM, Vasseur S, Keim V, Morisset J, Iovanna JL. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. Journal of Biological Chemistry 1997;272:32360–32369. [PubMed: 9405444]
- Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kundig TM, Amakawa R, Kishihara K, Wakeham A. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993;75:83–97. [PubMed: 8402903]
- Matzuk MM. Germ-line immortality. PNAS 2004;101:16395–16396. [PubMed: 15546980]
- McLean DJ, Johnston DS, Russell LD, Griswold MD. Germ cell transplantation and the study of testicular function. Trends in Endocrinology and Metabolism 2001;12:16–21. [PubMed: 11137036]
- Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. European Journal of Cancer 2005;41:2449–2461. [PubMed: 16199154]
- Mruk DD, Cheng CY. Cell-cell interactions at the ectoplasmic specialization in the testis. Trends in Endocrinology and Metabolism 2004a;15:439–447. [PubMed: 15519891]
- Mruk DD, Cheng CY. Sertoli-Sertoli and Sertoli-germ cell interactions and their significance in germ cell movement in the seminiferous epithelium during spermatogenesis. Endocrine Reviews 2004b; 25:747–806. [PubMed: 15466940]

- Mruk DD, Siu MKY, Conway AM, Lee NPY, Lau ASN, Cheng CY. Role of tissue inhibitor of metalloproteases-1 in junction dynamics in the testis. Journal of Andrology 2003;24:510–523. [PubMed: 12826691]
- Mruk DD, Wong C-H, Silvestrini B, Cheng CY. A novel male contraceptive specifically targeting germ cell adhesion. Nature Medicine 2006;12:1323–1328.
- O'Donnell L, Stanton PG, Bartles JR, Robertson DM. Sertoli cell ectoplasmic specializations in the seminiferous epithelium of the testosterone-suppressed adult rat. Biology of Reproduction 2000;63:99–108. [PubMed: 10859247]
- O'Donovan KJ, Tourtellotte WG, Millbrandt J, Baraban JM. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends in Neuroscience 1999;22:167–173.
- Oatley JM, Avarbock MR, Telaranta AI, Fearon DT, Brinster RL. Identifying genes important for spermatogonial stem cell self-renewal and survival. PNAS 2006;103:9524–9529. [PubMed: 16740658]
- Papadopoulos V, Dym M. Sertoli cell differentiation on basement membrane is mediated by the c-fos protooncogene. PNAS 1994;91:7027–7031. [PubMed: 8041740]
- Parvinen M. Regulation of the seminiferous epithelium. Endocrine Reviews 1982;3:404–417. [PubMed: 6295753]
- Petersen SL, Krishnan S, Hudgens ED. The aryl hydrocarbon receptor pathway and sexual differentiation of neuroendocrine functions. Endocrinology 2006;147:s33–s42. [PubMed: 16690800]
- Rossi DL, Hardiman G, Copeland NG, Gilbert DJ, Jenkins N, Zlotnik A, Bazan JF. Cloning and characterization of a new type of mouse chemokine. Genomics 1998;47:163–170. [PubMed: 9479488]
- Russell LD. Movement of spermatocytes from the basal to the adluminal compartment of the rat testis. American Journal of Anatomy 1977;148:313–328. [PubMed: 857632]
- Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors studies from gene knockout mice. Cytokine and Growth Factor Reviews 2001;12:133–142. [PubMed: 11325597]
- Schlecht U, Demougin P, Koch R, Hermida L, Wiederkehr C, Descombes P, Pineau C, Jegou B, Primig M. Expression profiling of mammalian male meiosis and gametogenesis identifies novel candidate genes for roles in the regulation of fertility. Moloecular Biology of the Cell 2004;15:1031–1043.
- Schneider-Maunoury S, Topilko P, Seitanidou T, Levi G, Cohen-Tannoudji M, Pournin S, Babinet C, Charnay P. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell 1993;75:1199–1214. [PubMed: 7903221]
- Schultz R, Penttila TL, Parvinen M, Persson H, Hokfelt T, Pelto-Huikko M. Expression of immediate early genes in tubular cells of rat testis. Biology of Reproduction 1995;52:1215–1226. [PubMed: 7632829]
- Shimasaki S, Moore RK, Otsuka F, Erickson GF. The bone morphogenetic protein system in mammalian reproduction. Endocrine Reviews 2004;25:72–101. [PubMed: 14769828]
- Siu MKY, Cheng CY. Interactions of proteases, protease inhibitors, and the β1 integrin/laminin γ3 protein complex in the regulation of ectoplasmic specialization dynamics in the rat testis. Biology of Reproduction 2004;70:945–964. [PubMed: 14645107]
- Siu MKY, Lee WM, Cheng CY. The interplay of collagen IV, tumor necrosis factor-α, gelatinase B (matrix metalloprotease-9), and tissue inhibitor of metalloproteases-1 in the basal lamina regulates Sertoli cell-tight junction dynamics in the rat testis. Endocrinology 2003a;144:371–387. [PubMed: 12488366]
- Siu MKY, Mruk DD, Lee WM, Cheng CY. Adhering junction dynamics in the testis are regulated by an interplay of β1-integrin and the focal adhesion complex-associated proteins. Endocrinology 2003b; 144:2141–2163. [PubMed: 12697723]
- Siu MKY, Wong C-H, Lee WM, Cheng CY. Sertoli-germ cell anchoring junction dynamics in the testis are regulated by an interplay of lipid and protein kinases. Journal of Biological Chemistry 2005;280:25029–25047. [PubMed: 15870075]
- Skinner, MK. Secretion of growth factors and other regulatory factors. In: Russell, LD.; Griswold, MD., editors. The Sertoli Cell. Clearwater, FL: Cache River; 1993. p. 238-247.

- Small CL, Shima JE, Uzumcu M, Skinner MK, Griswold MD. Profiling gene expression during the differentiation and development of the murine embryonic gonad. Biology of Reproduction 2005;72:492–501. [PubMed: 15496517]
- Stoughton RB. Applications of DNA microarrays in biology. Annual Review of Biochemistry 2005;74:53–82.
- Sultana T, Svechnikov KV, Gustafsson K, Wahlgren A, Tham E, Weber G, Söder O. Molecular identity, expression and functional analysis of interleukin-1α and its isoforms in rat testis. Asian Journal of Andrology 2004;6:149–153. [PubMed: 15154090]
- Sun H, Lu B, Li R-Q, Flavell RA, Taneja R. Defective T cell activation and autoimmune disorder in Stra13-deficient mice. Nature Immunology 2001;2:1040–1047. [PubMed: 11668339]
- Sushma Gurumurthy VMR. Par-4 inducible apoptosis in prostate cancer cells. Journal of Cellular Biochemistry 2004;91:504–512. [PubMed: 14755681]
- Swiatek PJ, Gridley T. Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20. Genes and Development 1993;7:2071–2084. [PubMed: 8224839]
- Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine and Growth Factor Reviews 2000;11:199–207. [PubMed: 10817963]
- Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. PNAS 1997;94:3801–3804. [PubMed: 9108058]
- Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. Seminars in Cancer Biology 2000;10:73–81. [PubMed: 10936058]
- Topilko P, Schneider-Maunoury S, Levi G, Trembleau A, Gourdji D, Driancourt M-A, Rao CV, Charnay P. Multiple pituitary and ovarian defects in Krox-24 (NGFI-A. Egr-1)-targeted mice. Molecular Endocrinology 1998;12:107–122. [PubMed: 9440815]
- Tourtellotte WG, Nagarajan R, Auyeung A, Mueller C, Milbrandt J. Infertility associated with incomplete spermatogenic arrest and oligozoospermia in Egr4-deficient mice. Development 1999;126:5061–5071. [PubMed: 10529423]
- Vasseur S, Hoffmeister A, Garcia-Montero A, Barthet M, Saint-Michel L, Berthezene P, Fiedler F, Closa D, Dagorn J, Iovanna J. Mice with targeted disruption of p8 gene show increased sensitivity to lipopolysaccharide and DNA microarray analysis of livers reveals an aberrant gene expression response. BMC Gastroenterology 2003;3:25–34. [PubMed: 12959645]
- Vihko KK, Penttila TL, Parvinen M, Belin D. Regulation of urokinase-and tissue-type plasminogen activator gene expression in the rat seminiferous epithelium. Molecular Endocrinology 1989;3:52– 59. [PubMed: 2536892]
- Wang X, Bo J, Bridges T, Dugan KD, Pan T-C, Chodosh LA, Montell DJ. Analysis of cell migration using whole-genome expression profiling of migratory cells in the *Drosophila* ovary. Developmental Cell 2006;10:483–495. [PubMed: 16580993]
- Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nature Cell Biology 2004;6:154–161.
- Wong C-H, Yan Cheng C. Mitogen-activated protein kinases, adherens junction dynamics, and spermatogenesis: A review of recent data. Developmental Biology 2005;286:1–15. [PubMed: 16153630]
- Wong C-H, Mruk DD, Lui WY, Cheng CY. Regulation of blood-testis barrier dynamics: an *in vivo* study. Journal of Cell Science 2004;117:783–798. [PubMed: 14734653]
- Wong C-H, Xia W, Lee NPY, Mruk DD, Lee WM, Cheng CY. Regulation of ectoplasmic specialization dynamics in the seminiferous epithelium by focal adhesion-associated proteins in testosteronesuppressed rat testes. Endocrinology 2005;146:1192–1204. [PubMed: 15591141]
- Xia W, Cheng CY. TGF-β3 regulates anchoring junction dynamics in the seminiferous epithelium of the rat testis via the Ras/ERK signaling pathway: an *in vivo* study. Developmental Biology 2005;280:321–343. [PubMed: 15882576]

- Xia W, Mruk DD, Lee WM, Cheng CY. Cytokines and junction restructuring during spermatogenesis a lesson to learn from the testis. Cytokine and Growth Factor Reviews 2005a;16:469–493. [PubMed: 16023885]
- Xia W, Wong C-H, Lee NPY, Lee WM, Cheng CY. Disruption of Sertoli-germ cell adhesion function in the seminiferous epithelium of the rat testis can be limited to adherens junctions without affecting the blood-testis barrier integrity: an *in vivo* study using an androgen suppression model. Journal of Cellular Physiology 2005b;205:141–157. [PubMed: 15880438]
- Xia W, Mruk DD, Lee WM, Cheng CY. Differential interactions between TGF-β3/TβR1, TAB1 and CD2AP disrupt blood-testis barrier and Sertoli-germ cell adhesion. Journal of Biological Chemistry 2006;281:16799–16813. [PubMed: 16617054]
- Yan HHN, Cheng CY. Blood-testis barrier dynamics are regulated by an engagement/disengagement mechanism between tight and adherens junctions via peripheral adaptors. PNAS 2005;102:11722– 11727. [PubMed: 16085710]
- Zawel L, Yu J, Torrance CJ, Markowitz S, Kinzler KW, Vogelstein B, Zhou S. DEC1 is a downstream target of TGF-β with sequence-specific transcriptional repressor activities. PNAS 2002;99:2848–2853. [PubMed: 11880636]
- Zhang J, Wong CH, Xia W, Mruk DD, Lee NPY, Lee WM, Cheng CY. Regulation of Sertoli-germ cell adherens junction dynamics via changes in protein-protein interactions of the N-cadherin-β-catenin protein complex which are possibly mediated by c-Src and MTMR2: an *in vivo* study using an androgen suppression model. Endocrinology 2005;146:1268–1284. [PubMed: 15591133]
- Zhou Q, Shima JE, Nie R, Friel PJ, Griswold MD. Androgen-regulated transcripts in the neonatal mouse testis as determined through microarray analysis. Biology of Reproduction 2005;72:1010–1019. [PubMed: 15601916]




Figure 1.

Morphological analysis of testes after Adjudin treatment and a summary of the gene expression profiles in testes at the time of extensive junction restructuring at the Sertoli–germ cell interface. (A; a–c). Paraffin sections of testes stained with hematoxylin in normal (Ctrl) rats (a) versus 8 h (b) and day 4 (c) after Adjudin treatment, spermatids were still loosely attached to Sertoli cells in the seminiferous epithelium by 8 h (b) post-treatment even though elongating spermatids and spermatocytes were found in lumen of most tubules examined versus day 4 (c), when virtually all spermatids were depleted from the epithelium, and control (Ctrl, normal) testes. Bar in a=40 µm which applies to (b and c); bar in inset in a=150 µm, which applies to insets in (b and c). (d) Changes in testis weight (per organ pair) after Adjudin treatment as a

result of germ cell loss (n=5). Percentage of testis weight in comparison with control (Ctrl, normal rats) testes was also annotated. ns, Not significantly different from control (normal) rats by ANOVA; *P < 0.01. (e) Each of the total of 31 099 probe sets on the Affymetrix GeneChip Rat Genome 230 2.0 array, was assigned a Flag to indicate its presence (P), marginal (M), or absence (A) based on the signal detected. The solid bar summarized the mean percentage of genes in each of the three groups from a total of eight samples (n=3 for control testes, n=2 for 8 h and n=3 for 4 days after Adjudin treatment). All the raw microarray data have been deposited at the Gene Expression Omnibus (GEO) data repository website: http://www.ncbi.nih.gov/geo/ with the accession number: GSE5131. (f and g) Normalized expression level of each gene at 8 h or at day 4 was plotted against its raw expression level (signal intensity) in control (Ctrl) testes. Each dot is a mean of data from two (8 h) or three (Ctrl and day 4) gene chips using different samples for hybridization. The two green lines above and below the green line marked at 1 represent a twofold change, namely induction or suppression, in gene expression level versus control. The color scheme (red signifies an increased expression and blue decreased expression) shown herein is the same as in Fig. 4A. (B) Venn diagram summarizing the number of genes with at least twofold changes in expression levels at 8 h and at day 4 from a total of 1466 transcripts that were found to be differentially regulated by one-way ANOVA.

Xia et al.




Figure 2.

Real-time RT-PCR quantification of the steady-state mRNA levels of selected target genes after Adjudin treatment by 8 h and day 4 versus control (Ctrl, normal testes). Note that the relative mRNA levels (fold changes against control) determined by real-time PCR for these nine genes were consistent with results of microarray experiments (see Tables 2–4). The activation of selected target genes during Adjudin-induced germ cell loss from the seminiferous epithelium as described herein have not previously been reported. ns, Not significantly different by ANOVA, *P<0.05; †P<0.01.

Xia et al.




Figure 3.

A study by immunoblotting and immunohistochemistry to assess changes in selected target proteins in rat testes after Adjudin treatment to validate microarray results. (A; a) Immunoblot analysis of cathepsin L in control (Ctrl), 8-h and 4-day rat testes. (b–d) Immunohistochemistry localization of cathepsin L in control, 8-h and 4-day testis respectively. Bar in *b*=70 µm, also applies to (c–d), as well as (b–d) in (B), (C) and (D). (B–D) Corresponding immunoblot analysis and immunohistochemistry results for α_2 -macroglobulin (α_2 -MG), testin, and claudin 3 respectively, similar to those shown in (A). The induction of testin during Adjudin-induced germ cell loss from the testis is consistent with earlier reports (Grima *et al.* 1997, Cheng *et al.* 2001), but changes of α_2 -MG and cathepsin or the unresponsiveness of claudin 3 have not been reported.

Xia et al.




Figure 4.

Hierarchical clustering of 1466 differentially regulated transcripts in rat testes from eight samples (n=3 for control (Ctrl) testes, n=2 for 8 h, n=3 for day 4 following Adjudin treatment). (A) Expression fold changes are depicted by the color map in the left panel. The dendrogram in the right panel illustrates that these 1466 probe sets displayed consistent patterns of up- or down-regulation by 8 h or 4 days after Adjudin treatment versus controls. Note that these patterns are consistent across different chips using different batches of samples within the same group. Five domains can be identified (a–e) that comprise the entire spectrum, which are also the five subtrees in the dengrogram (branches were removed without distracting the main diagram). These domains can be further grouped into two categories of i and ii, the subtrees at a higher level, which show a more pronounced mRNA induction at day 4 than 8 h (i) and vice versa (ii). Two boxed areas shown in (A) were selected and examined in detail and shown in (B) (top panel) and (C) (bottom panel). (B) Selected genes with significantly increased expression at day 4 but not at 8 h. (C) Selected genes with significant reduced expression at 8 h but not at day 4. The gene/Affymetrix IDs are listed on the right side of each row.

Table 1

Gene-specific primers for real-time RT-PCR

	Genbank accession number	Forward primer (sense, 5'–3')	Reverse primer (antisense, 5'–3')	Product length (bp)
Target gen	e			
Bhlhb2	NM_053328	5'-CCCACCCTTCTCCTTTATTGTG	5'-TACCGAGACATGCCAGTGTTG	106
c-fos	X06769	5'-TTCTCAATGACCCTGAGCCCA	5'-TGCCGGAAACAAGAAGTCATC	101
Cxcl10	BC058444	5'-TCCCTGTTTCTCCTGACCATG	5'-AGCCTTGCTGCTGGAGTTACT	101
IL-1α	NM_017019	5'-TTCCTCGTCCTAAGTCACTCGC	5'-TGGTTCCACTAGGCTTTGCTCT	101
Jun	NM_021835	5'-CCTTGAAAGCGCAAAACTCC	5'-CCCACTGTTAACGTGGTTCATG	101
Prss11	BC081767	5'-TAACACCTTGAAGGTGACGGC	5'-TTTTCCCTTTGGCCTGTCGA	101
Serping1	NM_199093	5'-TGAAGACATGGAAAAGGCACTC	5'-TGCGAGGCATCATCACGTAA	101
Stat3	NM_012747	5'-TCCCCCCGCACTTTAGATTCA	5'-TCCATGTCAAACGTGAGCGAC	101
Tnfrsf1a	NM_013091	5'-TGCCACGCAGGATTCTTTCT	5'-TTTGCAACTGGAGGTAGGCAC	101

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Table 2

Fold changes in the steady-state mRNA levels of selected target genes in Adjudin-treated rat testes during Sertoli-germ cell AJ restructuring which have been characterized in earlier studies

Time after Adjudin treatment (fold changes)

		8 h		Day 4		
	Target protein	Array data	Earlier study	Array data	Earlier study	Reference
Protein group						
AJ-integral membrane proteins	N-CADHERIN	2.09	2.5 (IB)	2.45	4.5 (IB)	Lee <i>et al.</i> (2004), Xia & Cheng (2005)
	NECTIN-3	1.01	– (IB)	0.72	0.25 (IB)	Xia & Cheng (2005)
	INTEGRIN-β1	1.82	2 (PCR) 1.5 (IB)	2.55	3.3 (PCR) 3–5.5 (IB)	Siu <i>et al.</i> (2003 <i>b</i>), Xia & Cheng (2005)
Adaptor proteins	α-CATENIN	0.96	– (IB)	1.65	5 (B)	Xia & Cheng (2005)
	β-CATENIN	1.12	2 (IB)	1.22	– (IB)	Lee et al. (2003)
	AXIN	0.92	– (IB)	0.92	0.5 (IB)	Lee et al. (2004)
	WASP	1.23	– (IB)	0.82	0.5 (IB)	Lee et al. (2004)
	NIXXZ	1.89	– (IB)	1.75	0.5 (IB)	Lee et al. (2004)
	p130 ^{CAS}	1.0	2 (IB)	1.05	0.75 (IB)	Siu et al. (2003b)
Protein kinases	p38 MAPK	1.0	– (IB)	1.36	– (IB)	Xia & Cheng (2005)
	ERK1	0.0	– (IB)	1.42	2 (B)	Xia & Cheng (2005)
	ERK2	0.96	– (IB)	1.1	2 (B)	Xia & Cheng (2005)
	c-SRC	2.06	3 (IB)	1.213	– (IB)	Lee & Cheng (2005)
	ROCKI	3.17	2.5 (B)	3.24	2 (B)	Lui et al. (2003a)
Actin-severing protein	COFILIN	1.3	4 (PCR)	1.6	2 (PCR)	Lui et al. (2003a)
Cytokine	TGF-β3	1.2	2.5 (B)	1.94	3 (B)	Xia & Cheng (2005)
Signaling proteins	RhoB GTPase	1.66	2.5 (B)	1.63	– (IB)	Lui et al. (2003a)
	TESTIN	2.2	2 (NB)	49.6	50 (NB)	Cheng <i>et al.</i> (2001), Grima <i>et al.</i> (2001)
	Rab8B	1.17	– (IB)	1.04	0.5 (B)	Lau & Mruk (2003)
Proteases/ protease inhibitors	TIMP-2	1.21	1.5 (B)	1.61	2.5 (B)	Siu & Cheng (2004)
	MMP2	0.88	– (IB)	1.59	0.9 (IB)	Siu & Cheng (2004)

-
_
_
-
ш.
1.1
σ
Ū
$\mathbf{\Sigma}$
-
-
₽
2
<u> </u>
t
5
5
Author
_
<
-
≤ Mar
=
<u> </u>
–
20
S
ISCI
¥.
<u> </u>
σ
<u> </u>

Time after Adjudin treatment (fold changes)

	dy Reference	Siu & Cheng (2004)
	Earlier study	– (IB)
Day 4	Array data	0.87
	Earlier study	– (IB)
8 h	Array data	0.71
	Target protein	MMP9

Xia et al.

IB, protein level detected by immunoblotting; PCR, steady-state mRNA level detected by RT-PCR; NB, steady-state mRNA level detected by northern blot; numbers indicate fold change relative to control samples which were generated by comparing the densitometrically scanned data; -, no significant changes; MMP, matrix metalloprotease; c-SRC, a non-receptor protein tyrosine kinase of the transforming gene of Rous sarcoma virus; TIMP, tissue inhibitor of metalloprotease; ROCK, Rho-associated protein kinase 1, also known as Rhoß; WASP, Wiskott-Aldrich syndrome protein.

NIH-PA Author Manuscript

Table 3

Selected target genes with greater than twofold changes in their steady-state mRNA levels by 8 h after Adjudin treatment at the time of extensive restructuring at the Sertoli–germ cell interface without the massive germ cell loss from the epithelium

Xia et al.

Accession numberSymbolSymbolBitDescriptionFrotin groupNM.017019III.a8.61.9DescriptionFrotin groupU.25200Cactor3.11.7Chemokine (C.X.C motif) ignatU.25200Cactor3.11.7Chemokine (C.X.C motif) ignatNM.013331Egr?5.31.3Early growth response 1NM.013332Egr?2.61.3Chemokine (C.X.C motif) ignatNM.013333Egr?2.61.3Chemokine (C.X.C motif) ignatNM.01334Egr?2.61.3Chemokine (C.X.C motif) ignatNM.13357NM.133582.11.4Chemokine (C.X.C motif) ignatNM.13358NM.133582.11.4Chemokine (C.X.C motif) ignatNM.13358NM.133582.11.42.61.4NM.13358NM.133582.11.42.61.4NM.13358NM.013581.42.61.42.6NM.01358NM.013581.41.42.61.4NM.01358NM.013581.41.42.61.4NM.01358NM.01358<				Adjudin treatr	Adjudin treatment (fold changes)	
NM_017019 IIIa 8.6 19 U22520 Cxct10 3.1 1.7 NM_01551 Egr1 8.5 1.5 NM_05333 Egr1 8.5 1.3 NM_05333 Egr1 8.5 1.3 NM_05333 Egr1 8.5 1.3 NM_05333 Egr2 5.3 1.1 BH0752 Bhihb2 3.5 1.1 BF407753 Bhihb2 3.5 1.1 BF40755 Jun 2.6 1.3 BF20425 Cam22 3.1 0.6 BF120425 Cam22 0.4 0.6 AV141214 Itgar_predicted 2.6 1.5 AV141214 Itgar_predicted 2.6 1.5 NM_05306 Krub6 2.8 1.6 NM_053306 Krub6 2.8 1.6 NM_053306 Krub6 2.8 1.6 NM_053306 Krub6 2.8 1.6 NM_053306 Krub		Accession number	Symbol	8 h	Day 4	Description
NM_017019 IIIa 86 19 U22520 $Cxcl10$ 3.1 1.7 NM_015551 $Egr1$ 8.5 1.3 NM_053533 $Egr2$ 5.3 1.3 NM_053533 $Egr2$ 5.3 1.3 NM_053533 $Egr2$ 5.3 1.3 NM_053533 $Egr2$ 5.3 1.3 NM_05333 $Egr2$ 5.3 1.3 BF40752 $Zut2$ 2.6 1.3 B120425 Jum 2.1 1.9 NM_133578 $Cg21$ 3.1 0.6 B120425 $Thibb2$ 3.1 0.6 B120425 $Thibb2$ 3.1 0.6 AW141214 $Itgour_prediced$ 2.6 1.5 AW141214 $Itgour_prediced$ 2.6 1.6 NM_05306 $Kenk6$ 2.6 1.6 NM_05306 $Kenk6$ 2.6 1.6 NM_053606 $Kenk6$ 2.6	Protein group					
U22520 Cxcl0 3.1 1.7 NM_012551 Egrl 8.5 1.5 NM_053633 Egrl 8.5 1.5 NM_053633 Egrl 8.5 1.5 NM_053633 Egrl 8.5 1.5 NM_053633 Egrl 3.5 1.1 BF40752 2.6 1.3 2.6 BF38619 Jun 2.1 1.9 NM_133578 Cpg21 3.1 0.6 BE120425 Cmt22 0.4 0.6 BF558056 Thab2 0.4 0.6 AW141214 Itgov_prediced 2.6 1.5 AW141214 Itgov_prediced 2.6 1.5 NM_055806 Kcnk6 2.8 1.9 NM_055806 Kcnk5 2.6 1.5 NM_055806 Kcnk6 2.8 1.9 NM_055806 Kcnk6 2.8 1.9 NM_055806 Kcnk5 2.8 1.9 NM_055806 <td< td=""><td>Cytokines</td><td>NM_017019</td><td>Illa</td><td>8.6</td><td>1.9</td><td>Interleukin 1α</td></td<>	Cytokines	NM_017019	Illa	8.6	1.9	Interleukin 1 α
NM_012551 Egrl 8.5 1.5 NM_053328 Egr2 5.3 1.3 NM_053328 Bhihb2 3.5 1.1 BF407732 Brihb2 3.5 1.1 BF3619 Jun 2.6 1.3 B128619 Jun 2.1 1.9 NM_133578 Cpg21 3.1 0.6 B128619 Jun 2.1 1.9 NM_133578 Cpg21 3.1 0.6 B1288056 Thib2 0.4 0.6 AW141214 Ingov_predicted 2.6 1.5 AW141214 Ingov_predicted 2.6 1.5 AW141214 Ingov_predicted 0.4 1.5 AW14124 Ingov_predicted 2.6 1.5 NM_053806 Kcnk6 2.8 1.9 NM_051604 Afpfi1 2.6 1.5 NM_053806 Knk6 2.8 1.4 NM_053806 Knk6 2.8 1.4 NM_05		U22520	Cxcl10	3.1	1.7	Chemokine (C-X-C motif) ligand 10
NM_05533 Epr2 5.3 1.3 NM_05328 Bthb2 3.5 1.1 BF407752 Brhb2 3.5 1.1 BF407753 Bribb2 3.5 1.1 BF407752 Jun 2.6 1.3 BF28619 Jun 2.1 1.9 NM_133578 Cpg21 3.1 0.6 BE120425 Cam/2g 0.4 0.6 BF120425 Cam/2g 0.4 0.6 AW141214 Igen_predicted 2.6 1.5 AW14124 Igen_predicted 0.4 0.6 AW14026 Kcuk6 2.8 1.9 NM_051604 Apford 0.4 1.5 NM_01504 Apford 0.4 1.6 NM_01504 Apford 2.1 1.4 NM_01504 Th 2.3 1.9 NM_01504 Th 2.3 1.4 NM_01504 Brg2 3.4 1.6 NM_012580 Mout<	Transcription factors	NM_012551	Egrl	8.5	1.5	Early growth response 1
NM_053238 Bhlhb2 3.5 1.1 BF407752 2.6 1.3 2.6 1.3 BF407752 1.m 2.6 1.3 2.6 1.3 BF407752 1.m 2.1 1.9 2.6 1.3 B128619 1.m 2.1 1.9 0.6 2.1 1.9 NM_133578 Cpg21 3.1 0.6 3.1 0.6 0.6 BF120425 Camk2g 0.4 0.6 0.4 0.6 AN141214 Itgav_predicted 2.6 1.5 0.6 AN17059 Mfup4_predicted 0.4 1.6 0.6 AN17059 Mfup4_predicted 0.4 1.5 0.6 NM_053806 Kcnk6 2.8 1.9 0.6 NM_053806 Kcnk6 2.8 1.9 0.6 NM_031604 7.0 0.3 1.1 1.4 NM_012401 Bf92 3.9 1.7 1.4 NM_0112580 Mesdc1_pred		NM_053633	Egr2	5.3	1.3	Early growth response 2
BF407752 2.6 1.3 B1288619 Jun 2.1 1.9 NM_133578 $Cpg21$ 3.1 0.6 BE120425 $Cmk2g$ 0.4 0.6 BF558056 $Thsb2$ 0.4 0.6 AN141214 $Itgav_predicted$ 2.6 1.5 AW141214 $Itgav_predicted$ 2.6 1.5 AW141214 $Itgav_predicted$ 2.6 1.5 AW141214 $Itgav_predicted$ 2.6 1.5 AW17059 $M/fap4_predicted$ 0.4 1.5 AW_053806 $Konb0$ 2.8 1.9 NM_053806 $Konb0$ 2.8 1.9 NM_031604 $ApfonIa$ 2.1 1.4 NM_012740 Th 0.3 0.6 B1288701 $Btg2$ 3.3 1.7 B1284349 $MydH6$ 3.5 1.7 B1284349 $MydH6$ 3.5 1.7 B1284349 $MydH6$ 3.5 1.7 A1407755 $Mesdc1_predicted$ 2.1 1.4 <td< td=""><td></td><td>NM_053328</td><td>Bhlhb2</td><td>3.5</td><td>1.1</td><td>Basic helix-loop-helix domain containing, class B2</td></td<>		NM_053328	Bhlhb2	3.5	1.1	Basic helix-loop-helix domain containing, class B2
BI288(19) Jm 2.1 1.9 NM_133578 $Cpg21$ 3.1 0.6 BE120425 $Camb2g$ 0.4 0.6 BE120425 $Camb2g$ 0.4 0.6 BE120425 $Camb2g$ 0.4 0.6 BE120425 $Thsb2$ 4.2 1.6 AW141214 $Igav_predicted$ 2.6 1.5 AW141214 $Igav_predicted$ 2.6 1.5 AW14059 $Kenk6$ 2.6 1.5 NM_053806 $Kenk6$ 2.8 1.9 NM_053806 $Kenk6$ 2.8 1.9 NM_012740 Th 0.4 1.6 NM_012740 Th 0.3 0.3 B1288701 $Brg2$ 3.9 1.3 B1288701 $Brg2$ 3.5 1.7 B1294414 $Spr1_Ipredicted$ 3.4 1.6 NM_012580 $Hmoxl2.11.6AI407755Mesdc1_Ipredicted2.11.6NM_012580Hmoxl2.11.6NM_012580MiH40.51.0$		BF407752		2.6	1.3	AT-rich interactive domain 1A (Swi1-like; predicted)
NM_133578 $Cpg21$ 3.1 0.6 BE120425 $Camk2g$ 0.4 0.6 BE120425 $Camk2g$ 0.4 0.6 BF558056 $Thb2$ $Camk2g$ 0.4 0.6 BF558056 $Thb2$ 4.2 1.6 0.6 AW141214 $Irgav_predicted$ 2.6 1.5 1.5 ANL053806 $Kenk6$ 2.6 1.5 1.6 NM_053806 $Kenk6$ 2.8 1.9 1.6 NM_053806 $Kenk6$ 2.8 1.9 1.6 NM_01509 N_m01a 2.1 1.4 1.6 NM_01240 Th 0.3 0.6 1.3 B1284349 $Myd116$ 3.5 1.7 1.6 NM_012580 $Myd116$ 3.5 1.7 1.6 B1284349 $Myd116$ 3.5 1.7 1.6 NM_012580 $Mosdc1_Dredicted$ 3.4 1.6 1.6 </td <td></td> <td>BI288619</td> <td>Jun</td> <td>2.1</td> <td>1.9</td> <td>v-jun sarcoma virus 17 oncogene homolog (avian)</td>		BI288619	Jun	2.1	1.9	v-jun sarcoma virus 17 oncogene homolog (avian)
BEI20425 Camk2g 0.4 0.6 BF558056 $Thb2$ 4.2 1.6 AN141214 $Irgav_predicted$ 2.6 1.5 AN141214 $Irgav_predicted$ 2.6 1.5 AN177059 $Mfap4_predicted$ 0.4 1.5 ANL053806 $Kcnk6$ 2.8 1.9 NM_053806 $Kcnk6$ 2.8 1.9 NM_053806 $Kcnk6$ 2.8 1.9 NM_053806 $Kcnk6$ 2.8 1.9 NM_012740 Th 0.3 0.5 B1284349 $Myd116$ 3.9 1.7 B1284349 $Myd116$ 3.5 1.7 B1284349 $Myd116$ 3.5 1.7 B1284349 $Myd116$ 3.5 1.7 B1284349 $Myd116$ 3.5 1.7 B1284349 $Myd116$ 3.4 1.6 Al407755 $Mesdc1_predicted$ 2.1 1.6 Al40777	Kinases/phosphatases	NM_133578	Cpg2I	3.1	0.6	MAP-kinase phosphatase (cpg21)
BF558056Thsb2Thsb21.6AW141214Igav_predicted2.61.5AW141214Igav_predicted2.61.5AN177059 $Mfqp4_predicted2.61.5AN_053806Kenk62.81.9NM_053805Kenk62.81.9NM_012740Th0.30.6NM_012740Th0.30.6B1288701Big23.91.7B128499Myd1163.51.7B1294414Spry1_predicted3.41.6A1407755Mexdc1_predicted2.11.6A1407755Mexdc1_predicted2.11.6A1598401Pim12.01.2NM_13413Bibd14p0.51.0$		BE120425	Camk2g	0.4	0.6	Calcium/calmodulin-dependent protein kinase II γ
AW141214Igav_predicted 2.6 1.5 Al177059 $Mfap4_predicted$ 0.4 1.5 Al177059 $Mfap4_predicted$ 0.4 1.5 NM_053806 $Kcnk6$ 2.8 1.9 NM_012740 $Krnk6$ 2.8 1.9 NM_012740 Th 0.3 0.5 B1288701 $Big2$ 3.9 1.3 B1288701 $Big2$ 3.9 1.7 B1284709 $Myd116$ 3.5 1.7 B1294414 $Spry1_predicted$ 3.4 1.6 A1407755 $Mesdc1_predicted$ 2.2 1.4 A1407756 $Pim1$ 2.0 1.6 NM_13413 $Pim1$ 2.0 1.2 NM_13413 $Bibd14p$ 0.5 1.0	Cell adhesion molecules	BF558056	Thsb2	4.2	1.6	Thrombospondin 2 (predicted)
A1177059 $Mfap4_{predicted}$ 0.4 1.5 NM_053806 $Kcnk6$ 2.8 1.9 NM_053804 $Kcnk6$ 2.8 1.9 NM_012740 $Ap6nIa$ 2.1 1.4 NM_012740 Th 0.3 0.5 $B1283701$ $Big2$ 3.9 1.3 $B1283701$ $Big2$ 3.9 1.3 $B128349$ $MydI16$ 3.5 1.7 $B1284349$ $MydI16$ 3.5 1.7 $B129414$ $SpryLpredicted$ 3.4 1.6 $A140775$ $MesdcLpredicted$ 2.2 1.4 NM_012580 $HmoxI$ 2.0 1.6 NM_012580 PmI 2.0 1.6 NM_13413 PmI 0.5 1.0		AW141214	Itgav_predicted	2.6	1.5	Similar to integrin α subunit (LOC296456)
NM_053806 Kenk6 2.8 1.9 NM_031604 $Ap6nIa$ 2.1 1.4 NM_012740 Th 0.3 0.6 NM_012740 Th 0.3 0.6 B1288701 $Brg2$ 3.9 1.7 B1284349 $Myd116$ 3.5 1.7 Al407755 $Mesdc1_predicted$ 2.2 1.4 NM_012580 $HmoxI$ 2.1 1.6 NM_012580 $PimI$ 2.0 1.2 NM_134413 $Bibd14b$ 0.5 1.0		A1177059	Mfap4_predicted	0.4	1.5	Microfibrillar-associated protein 4 (predicted)
NM_031604 Apbnia 2.1 1.4 NM_012740 Th 0.3 0.6 NM_012740 Th 0.3 0.6 B1288701 $Big2$ 3.9 1.3 B1284349 $Myd116$ 3.5 1.7 B1284349 $Myd116$ 3.5 1.7 B1294414 $Spry1_predicted$ 3.4 1.6 A1407755 $Mesdc1_predicted$ 2.2 1.4 A1407755 $Mesdc1_predicted$ 2.2 1.4 A1407755 $Mesdc1_predicted$ 2.2 1.4 A1598401 $Pin1$ 2.0 1.6 A1598401 $Pin1$ 2.0 1.2 NM_13413 $Btbd14b$ 0.5 1.0	Ion homeostasis regulators	NM_053806	Kcnk6	2.8	1.9	Potassium channel, subfamily K, member 6 (TWIK-2)
NM_012740 Th 0.3 0.6 B128701 $Big2$ 3.9 1.3 B1288701 $Big2$ 3.9 1.3 B1288701 $Big2$ 3.9 1.3 B1284349 $Myd116$ 3.5 1.7 B1294414 $SpryLpredicted$ 3.4 1.6 A1407755 $MesdcLpredicted$ 2.2 1.4 A1407756 $MesdcLpredicted$ 2.2 1.4 A1598401 $Pinl$ 2.0 1.6 A1598401 $Pinl$ 2.0 1.2 NM_134413 $Bibd14b$ 0.5 1.0		NM_031604	Atp6n1a	2.1	1.4	ATPase, H ⁺ transporting, lysosomal non-catalytic accessory protein 1a
BI288701 $Big2$ 3.9 1.3 BI284349 $Myd1I6$ 3.5 1.7 BI294414 $Spry1_predicted$ 3.5 1.7 BI294414 $Spry1_predicted$ 3.4 1.6 AI407755 $Mesdc1_predicted$ 2.2 1.4 AI407755 $Mesdc1_predicted$ 2.2 1.4 AI407755 $Mesdc1_predicted$ 2.2 1.4 AI407755 $Mesdc1_predicted$ 2.2 1.4 NM_0102580 $HmoxI$ 2.1 1.6 AI598401 $PimI$ 2.0 1.2 NM_13413 $Btbd14b$ 0.5 1.0		NM_012740	Th	0.3	0.6	Tyrosine hydroxylase
Myd116 3.5 1.7 Spry1_predicted 3.4 1.6 Mesdc1_predicted 2.2 1.4 Hmox1 2.1 1.6 Pin1 2.0 1.2 Bibd14b 0.5 1.0	Signaling molecules	BI288701	Bt_g2	3.9	1.3	B-cell translocation gene 2, anti-proliferative
Spry1_predicted 3.4 1.6 Mesdc1_predicted 2.2 1.4 Hmox1 2.1 1.6 Pin1 2.0 1.2 Btbd14b 0.5 1.0		BI284349	Myd116	3.5	1.7	Myeloid differentiation primary response gene 116
Mesdcl_predicted 2.2 1.4 Hmoxl 2.1 1.6 Pinl 2.0 1.2 Btbd14b 0.5 1.0		BI294414	Spry1_predicted	3.4	1.6	Similar to sprouty 1 (LOC294981), mRNA
Hmox1 2.1 1.6 Pin1 2.0 1.2 Bibd14b 0.5 1.0		A1407755	Mesdc1_predicted	2.2	1.4	Mesoderm development candidate 1 (predicted)
Pin1 2.0 1.2 Blbdl4b 0.5 1.0		NM_012580	Hmox1	2.1	1.6	Heme oxygenase; Heme oxygenase 1
Btbd14b 0.5 1.0		AI598401	PimI	2.0	1.2	Proviral integration site 1
		NM_134413	Btbd14b	0.5	1.0	BTB (POZ) domain containing 14B

_
~
_
_
_
_
- U
-
D
-
-
_
t
_
Jtho
\sim
0
_
~
<
Mar
01
<u> </u>
_
_
_
5
5
0
S
0
_⊇.
0
-

NIH-PA Author Manuscript

Table 4

Selected target genes with greater than twofold changes in their steady-state mRNA levels by day 4 after Adjudin treatment at the time of germ cell loss from the seminiferous epithelium

Adjudin treatment (fold

			changes)		
	Accession number	Symbol	8 h	Day 4	Description
Protein group					
Cytokines/receptors	BF283398	Cxcl12	1.0	5.3	Chemokine (C-X-C motif) ligand 12
	BM383766	1117re	1.0	5.1	Similar to interleukin 17 receptor E isoform 1
Transcription factors	NM_053611	Nuprl	1.4	5.4	Nuclear protein 1
	U05989	Pawr	1.3	4.1	PRKC, apoptosis, WT1, regulator
Ion homeostasis regulators	BG378926	S100a11_predicted	0.0	7.3	S100 calcium-binding protein A11 (calizzarin) (predicted)
	BF401956	Trfr2_predicted	0.8	6.5	Similar to transferrin receptor protein 2 (TfR2) (LOC288562)
	BF412731	Pdyn	1.0	6.2	Prodynorphin
	NM_130741	Lcn2	1.2	5.9	Lipocalin 2
	NM_053469	Hamp	2.0	4.9	Hepcidin antimicrobial peptide
	NM_012733	RbpI	1.2	4.1	Retinol-binding protein 1
Proteases/protease inhibitors	NM_031531	Spin2c	1.5	26.0	Serine protease inhibitor
	NM_053819	Timp1	1.7	15.0	Tissue inhibitor of metalloproteinase 1
	BF411331	Serpinb1a_predicted	0.0	6.8	Similar to serine (or cysteine) proteinase inhibitor, clade B, member 1b
	AW915763	Serping1	1.3	4.9	Serine (or cysteine) proteinase inhibitor, clade G (Cl inhibitor), member 1, (angioedema, hereditary)
	NM_031721	Prss11	1.0	4.1	Protease, serine, 11
Cytoskeleton inter-acting proteins	BI296155		1.6	5.6	Filamin, β , transcript variant 3 (Flnb) predicted
	BE109711	Lcp1_predicted	1.1	4.8	Similar to lymphocyte cytosolic protein 1 (LOC306071)
	BM392410	Myh9	1.3	4.6	Myosin, heavy polypeptide 9
Cell adhesion molecules	NM_133298	Gpnmb	1.6	13.6	Glycoprotein (transmembrane) nmb
Signaling molecules	NM_133624	Gbp2	1.9	5.2	Guanylate-binding protein 2, interferon-inducible
	AW917760		1.3	7.9	Similar to myoferlin (Fer-1-like protein 3)
	H31511	Trim2	1.5	6.0	Tripartite motif protein 2 (protein ubiquitination)

_
_
~~
_ ⊳
~
\rightarrow
_
=
<u> </u>
Jtho
$\mathbf{\underline{\vee}}$
_
~
Mar
01
L
_
_
S
JSCI
\sim
 .
0
+

Adjudin treatment (fold changes)

NIH-PA Author Manuscript

Xia et al.	

Accession number	Symbol	8 h	Day 4	Description
NM_019386	Tgm2	1.2	4.1	Tissue-type transglutaminase, C polypeptide
BF282318		1.6	5.4	Similar to Bq135360 (LOC292922; acute-phase response)
BM387864		1.8	5.3	Similar to FLI-LRR-associated protein-1
Y00480	RTI-Da	1.1	5.3	Rat MHC class II RT1, locus Da
BI285865	Tagln2_predicted	1.4	5.3	Similar to transgelin 2; SM22- α homolog (LOC304983)
M25719	Pam	0.9	5.1	Peptidylglycine a-amidating monooxygenase
BI274355	Olfml3_predicted	1.0	4.9	Olfactomedin-like 3 (predicted)
D88250	CIs	1.1	4.8	Complement component 1, s subcomponent
BI285347	C4a	1.2	6.0	Palmitoyl-protein thioesterase 2

_
_
~
\leq
_
U
~
-
-
-
-
utho
~
0
-
_
<
Nan
0)
<u> </u>
_
-
SC
S
Ö
C)
_
<u></u>
75
<u> </u>

NIH-PA Author Manuscript

Table 5

Selected target genes with greater than twofold changes in their steady-state mRNA levels by 8 h and day 4 after Adjudin treatment

Xia et al.

			Adjudin treatment (fold change)	old change)	
	Accession number	Symbol	8 h	Day 4	Description
Protein group					
Cytokines/receptors	NM_030845	Cxcl1	62.6	6.8	Chemokine (C-X-C motif) ligand 1
	NM_031530	Ccl2	8.1	5.2	Chemokine (C-C motif) ligand 2
	NM_017020	ll6r	4.0	8.1	Interleukin 6 receptor
	BI303379	Tnfrsf12a	3.8	8.4	Tumor necrosis factor receptor superfamily, member 12a
	NM_134455	Cx3cl1	3.2	5.3	Chemokine (C-X3-C motif) ligand 1
	NM_030997	Vgf	3.0	16.1	VGF nerve growth factor inducible
	NM_013091	Tufrsfla	2.2	6.1	Tumor necrosis factor receptor superfamily, member 1a
Transcription factors	BF415939	c-fos	26.8	3.5	c-fos oncogene
	NM_012912	Atf3	15.1	11.2	Activating transcription factor 3
	AI716248		3.4	4.9	Similar to RIKEN cDNA 9230117N10 (LOC361749), nucleus protein (predicted)
	NM_012591	Irf1	2.1	4.1	Interferon regulatory factor 1
	NM_012603	Myc	2.1	2.7	v-myc avian myelocytomatosis viral oncogene homolog
	BE113920	Stat3	2.0	2.6	Signal transducer and activator of transcription 3
Cell adhesion molecules	AI406660	Thbs1	6.0	2.4	Thrombospondin 1
	BE110753	Itga6	3.3	3.6	Integrin α6
	AI408095	Smagp	2.9	4.6	Small cell adhesion glycoprotein
Proteases	NM_013151	Plat	2.8	3.1	Plasminogen activator, tissue type
	AI232474	Ctsl	2.5	3.1	Cathepsin L
Transporters	NM_012532	Cp	2.7	4.2	Ceruloplasmin
	NM_031325	Ugdh	2.6	3.6	UDP-glucose dehydrogenase
	NM_053318	Hpx	4.0	46.2	Hemopexin
Signaling molecules	AI176519	Ler3	9.7	4.3	Immediate early response 3
	AA800587	Gpx2	2.8	7.0	Glutathione peroxidase 2

_
_
_
- T-
- <u></u>
U
~
—
2
tho
-
· ·
~
\sim
5
<u>u</u>
=
1
0
~
0
-
0
_

nuscript

~	
~	
_	
<u> </u>	
0	
· · ·	
-	
-	
<u> </u>	
-	
Autho	
_	
0	
<u> </u>	
_	
<	
<u> </u>	
=	
_	

		Adjudin treat	Adjudin treatment (fold change)	
Accession number	Symbol	8 h	Day 4	Description
BF420334	Rab20_predicted	2.7	2.5	Similar to rab20 (LOC364641) mRNA
AI703807	Crim1_predicted	2.3	5.9	Cysteine-rich motor neuron 1 (predicted)
AA901350		2.3	5.9	Guanylate nucleotide-binding protein 3 (predicted)
U16858	Testin	2.2	49.6	Testin
BE099056	Grtp1_predicted	2.2	3.0	Similar to GH-regulated TBC protein 1 (LOC361180), mRNA
BF412519	Ripk2_predicted	2.2	4.1	Receptor (TNFRSF)-interacting serine- threonine kinase 2 (predicted)
NM_054008	Rgc32	2.1	2.8	Response gene to Complement 32 (cyclin- dependent kinase regulation)
BE113215	Trim47_predicted	2.1	4.0	Tripartite motif protein 47 (predicted; protein ubiquitination)
BI294994	Optn	2.1	2.5	Optineurin

	References	Lee <i>et al.</i> (1996), Topilko <i>et al.</i> (1998), O'Donovan <i>et al.</i> (1999)	Schneider-Maunoury <i>et al.</i> (1993), Swiatek & Gridley (1993)	Sun <i>et al.</i> (2001), Zawel <i>et al.</i> (2002)	Alcivar et al. (1990), Johnson et al. (1993), Schultz et al. (1995)	Mallo <i>et al.</i> (1997), Garcia-Montero <i>et al.</i> (2001), Vasseur <i>et al.</i> (2003)	Garcia-Cao et al. (2003), Lafuente et al. (2003), Sushma Gurumurthy (2004), Goswami et al. (2006)	Johnson et al. (1992), Papadopoulos & Dym (1994), Schultz et al. (1995), Milde- Langosch (2005)	Hai & Hartman (2001), Hartman <i>et al.</i> (2004)	Matsuyama <i>et al.</i> (1993), Tanaka & Taniguchi (2000), Sato <i>et al.</i> (2001)	Koji <i>et al.</i> (1988), Davis <i>et al.</i> (1993), Lim <i>et al.</i> (1994), Lim & Hwang (1995)	Jenab & Morris (1997), Takeda <i>et al.</i> (1997), Takeda & Akira (2000)
gnificantly induced during Adjudin-induced anchoring junction restructuring in the testis	Studies in testes	Cultured Sertoli cells; Leydig cells	n.k.	n.k.	Spermatogonia, pre-leptotene spermatocytes	n.k.	n.k.	Cultured Sertoli cells	n.k.	Cultured Sertoli cells	Spermatogonia	Cultured Sertoli cells
luring Adjudin-induced anchori	Function	Regulates LH-β expression	Brain development	Transcription repressor; required for cytokine production; activated by TGF-β	Multiple functions: JNK signaling: stage-specific expression	Enhances TGF-β1-smad signaling	Transcription corepressor; mediates TNFα-induced apoptosis	Regulates Sertoli cell differentiation on basement membrane; stage- specific expression	Stress response	Regulates interferon expression	Multiple functions: testosterone and FSH induce c-Myc expression in cultured Sertoli cells	Multiple functions: regulates IL-6 and IFN- γ mediated gene expression in Sertoli cells
	KO phenotype	Female infertile; male fertile or sterile	Perinatal lethality	Normal, aging mice develop autoimmune disease	Embryonic-perinatal lethality	Normal: increased sensitivity to lipopolysaccharide	Splenomegaly	Reduced viability and size, impaired gametogenesis	Normal	Nomal	Embryonic lethality; heterozygous females with reduced fertility	Embryonic lethality
Summary of transcription factors that are si	Other names	Transcription factors <i>Egr1</i> NGFI-A/Krox-24/zif/268	Krox-20	SHARP-2/Stra13/DEC1	n.a.	Nuclear protein p8	Par-4	n.a.	LRF-1/LRG-21/CRG-5/TI-241	n.a.	n.a.	n.a.
Summary		Transcriț Egrl	Egr2	Bhlhb2	Jun	Nupr1	Pawr	c-fos	Atf3	Irf1	Myc	Stat3

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Table 6

NIH-PA Author Manuscript

Xia et al.

Rank	Input gene/pathway gene	Signaling pathway	Impact factor	P value	Input gene/pathway gene	Signaling pathway	Impact factor	P value
1	7/43	Phosphatidylinositol signaling	89.4	0.017	7/43	Phosphatidylinositol signaling	104	0.017
2	13/109	Focal adhesion	67	0.045	13/109	Focal adhesion	87.2	0.045
JE ω	16/110	Cytokine-cytokine receptor interaction	63.8	0.005	16/110	Cytokine-cytokine receptor interaction	76.4	0.005
Indoo 4	21/153	MAPK signaling	56.4	0.004	10/85	Tight junction	74.9	0.067
crinc vo	10/85	Tight junction	42.1	0.067	21/153	MAPK signaling	53.8	0.004
ol. A o	11/66	Apoptosis	34.5	0.005	11/66	Apoptosis	48.6	0.005
utho	13/161	Calcium signaling	32.8	0.380	13/161	Calcium signaling	37.6	0.380
r ma ∞	8/49	Toll-like receptor signaling	23.4	0.013	8/49	Toll-like receptor signaling	34	0.013
nuscript; available in PMC 2010 January 9								

Ranking of top signaling pathways in Adjudin-treated testes identified by Pathway Express

NIH-PA Author Manuscript

Table 7

NIH-PA Author Manuscript